

Visible-light-Induced 1,2-Diphenyldisulfane-Catalyzed Regioselective
Hydroboration of Electron-Deficient Alkenes

Yu-Qi Miao^a, Qiao-Jing Pan^a, Zhenxing Liu^{b*}, Xuenian Chen^{a,b*}

Affiliations:

^aHenan Key Laboratory of Boron Chemistry and Advanced Energy Materials,
School of Chemistry and Chemical Engineering, Henan Normal University,
Xinxiang, Henan, China.

^bCollege of Chemistry, Zhengzhou University, Zhengzhou, Henan, China.

***Corresponding Author:** [Xuenian Chen@zzu.edu.cn](mailto:Xuenian_Chen@zzu.edu.cn) (X. C), Liuzhenxing@zzu.edu.cn
(Z. L.)

Table of Contents


1. General information.....	2
2. Synthesis of Starting Materials.....	2
3. Procedure for the hydroboration of electron-deficient alkenes.....	5
4. Gram scale and mechanistic experiments.....	6
5. Characterization data of products.....	7
6. Characterization data of starting materials.....	24
7. References.....	32
8. NMR Spectra.....	33

1. General information

All the reagents were purchased from commercial suppliers and used without further purification, unless otherwise stated. Reactions were monitored by thin layer chromatography (TLC) using performed on commercial silica gel plates, and flash column chromatography was performed with 200–300 mesh silica gel. The CFL lamp and Blue LEDs were purchased from the supermarket. ^1H NMR, ^{13}C NMR, ^{11}B NMR and ^{19}F NMR spectra were recorded on 600 MHz spectrometer in CDCl_3 or DMSO at room temperature. Chemical shifts (δ) are reported in ppm relative to the solvent peak. The ^{11}B and $^{11}\text{B}\{\text{H}\}$ NMR spectra were obtained at 128 or 193 MHz. All ^{11}B chemical shifts are referenced to $\text{BF}_3 \cdot \text{OEt}_2$ (0.0 ppm), with a negative sign indicating an upfield shift. Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), q (quartet), with coupling constants (J) in hertz (Hz).


2. Synthesis of Starting Materials

2.1 Procedure for preparation of NHC- BH_3 using the literature report¹



A 100 mL Schlenk-tube was charged with 1-methylimidazole (8.2 g, 100 mmol, 1.0 equiv.) and DCM (20 mL) was added. Iodomethane (16.9 g, 120 mmol, 1.2 equiv.) was subsequently added slowly over 10 min at 0 °C. Then the reaction was left to stir at room temperature for 2 hours. After this time the solvent was removed under vacuum and got the crude product, which toluene (50 mL) and NaBH_4 (4.53 g, 120 mmol, 1.2 equiv.) was then added. And the mixture was heated at 120 °C for 24 h. The hot reaction solvent was cautiously decanted from the insoluble mixture, then the reaction flask was washed with hot toluene (2 × 20 mL). The organic extracts were combined, evaporated, and purified by recrystallization from boiling water to give the 5.3 g pure product as a fine white crystal in a 48% yield.

2.2 Starting electron-deficient alkenes



2.3 Procedure for the Synthesis of 1n²

To a 50 mL Schlenk flask equipped with 7-hydroxycoumarin (486 mg, 3.0 mmol, 1.0 equiv.), 1-chloro-3-methylbut-2-ene (374mg, 3.6 mmol, 1.2 equiv.), and potassium carbonate (1.24 g, 9 mmol, 3.0 equiv.) in DMF (15 mL). The mixture was stirred at 100 °C for 10 h. After the starting material was consumed, monitored by TLC. The mixture was cooled to room temperature and dissolved in ethyl acetate. The organic layer was washed with water, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the product **1n**.

2.4 Procedure for the Synthesis of 1q-1t³


To a 50 mL Schlenk flask equipped with aniline (3.0 mmol, 1.0 equiv.), potassium carbonate (420 mg, 3.0 mmol, 1.0 equiv.) in DCM (15 mL), which crotonyl chloride (374 mg, 3.6 mmol, 1.2 equiv.) was added by syringe under N₂ atmosphere. After the starting material was consumed, monitored by TLC. The mixture was poured into H₂O, extracted with ethyl acetate (3 × 15 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **1q-1t**.

2.5 Procedure for the Synthesis of 1w-1aa¹⁰

To a 50 mL Schlenk flask equipped with NaH (3.6 mmol, 1.2 equiv.) in dry THF, which was added diethyl(cyanomethyl)phosphonate (3.6 mmol, 1.2 equiv.) at 0 °C under N₂ atmosphere. The reation was stirred at room temperature for 0.5 h before adding the solution of aldehyde (3 mmol, 1.0 equiv.). The starting material was consumed, monitored by TLC. The mixture was quenched with saturated NH₄Cl (aq.). The mixture


was extracted with ethyl acetate (3×15 mL), the organic layer was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **1w-1aa**.

2.6 Procedure for the Synthesis of **1ab**, **1ac**⁷




To a 50 mL Schlenk flask equipped with ethynylbenzene (3.0 mmol, 1.0 equiv.), PhSO_2Na (3.6 mmol, 1.2 equiv.), CuCl (0.15 mmol, 0.05 equiv.), 4,4',5,5'-tetrahydro-2,2'-bioxazole (0.15 mmol, 0.05 equiv.) in AcOH (3 mL), DMI (3 mL), H_2O (3 mL). The mixture was stirred at 60 °C for 18 h under air atmosphere. After the mixture was poured into H_2O , extracted with ethyl acetate (3×15 mL), dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **1ab**, **1ac**.

2.7 Procedure for the Synthesis of **1ad-1ai**⁶




To a 20 mL pressure equipped with aryl iodine (3.0 mmol, 1.0 equiv.), diethyl vinylphosphonate (3.0 mmol, 1.0 equiv.), $\text{Pd}(\text{OAc})_2$ (0.06 mmol, 0.02 equiv.), K_2CO_3 (3.0 mmol, 1.0 equiv.) in DMF (10 mL). The reaction was heated at 110 °C for 10 h. Then the mixture was poured into H_2O , extracted with ethyl acetate (3×15 mL), dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **1ad-1ai**.

2.8 Procedure for the Synthesis of **1aj-1al**⁵



To a 50 mL Schlenk flask equipped with substrate 1 (3.0 mmol, 1.0 equiv.), CuCl (0.6 mmol, 0.2 equiv.), Ag_2CO_3 (1.8 mmol, 0.6 equiv.), and NaSO_2CF_3 (9.0 mmol, 3.0 equiv.) in DCE (15 mL) at 0 °C, which was slowly added TBHP (15 mmol, 5.0 equiv.). The reaction was heated under refluxing for 24h. Then the mixture was extracted with ethyl acetate (3×15 mL), the organic layer was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **1aj-1al**.

2.9 Procedure for the Synthesis of **1am**, **1an**⁸



To a 50 mL Schlenk flask equipped with ethynylbenzene (3.0 mmol, 1.0 equiv.), HBpin (3.6 mmol, 1.2 equiv.), LiHMDS (0.3 mmol, 0.1 equiv.) in toluene (15 mL). The mixture was stirred at 80 °C for 18 h under N₂ atmosphere. After the mixture was poured into H₂O, extracted with ethyl acetate (3 × 15 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **1am**, **1an**.

3. Procedure for the hydroboration of electron-deficient alkenes.

3.1 General Procedure for the hydroboration of 1a-1e, 1i-1p, 1u, 1v-1aa.

To a 10 mL Schlenk flask equipped with alkenes (0.2 mmol, 1.0 equiv.), NHC-borane (28.6 mg, 0.26 mmol, 1.3 equiv.), PhSSPh (4.4 mg, 0.02 mmol, 0.1 equiv.) in EtOH (2 mL) under N₂ atmosphere. Then the reaction was placed at a distance (app. 5 cm) from 23W CFL lamp and the mixture was stirred for 24 h at room temperature. Then the reaction was concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **3a-3e**, **3i-3p**, **3u**, **3v-3aa**.

3.2 General Procedure for the hydroboration of 1f-1h.

To a 10 mL Schlenk flask equipped with alkenes (0.2 mmol, 1.0 equiv.), NHC-borane (28.6 mg, 0.26 mmol, 1.3 equiv.), PhSSPh (4.4 mg, 0.02 mmol, 0.1 equiv.) in MeCN (2 mL) under N₂ atmosphere. Then the reaction was placed at a distance (app. 5 cm) from 23W CFL lamp and the mixture was stirred for 24 h at room temperature. Then the reaction was added 5 mL H₂O, extracted with DCM (3 × 10 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **3f-3h**.

3.3 General Procedure for the hydroboration of 1q, 1s.

To a 10 mL Schlenk flask equipped with alkenes (0.2 mmol, 1.0 equiv.), NHC-borane (44 mg, 0.4 mmol, 2 equiv.), PhSSPh (8.8 mg, 0.04 mmol, 0.2 equiv.) and THF (2 mL) under N₂ atmosphere. Then the reaction was placed at a distance (app. 5 cm) from 10W blue LEDs (410-420 nm) lamp and the mixture was stirred for 24 h at room temperature. Then the reaction was added 5 mL H₂O, extracted with DCM (3 × 10 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **3q**, **3s**.

3.4 General Procedure for the hydroboration of 1r, 1t.

To a 10 mL Schlenk flask equipped with alkenes (0.2 mmol, 1.0 equiv.), NHC-borane (44 mg, 0.4 mmol, 2 equiv.), PhSSPh (8.8 mg, 0.04 mmol, 0.2 equiv.) and THF (2 mL) under N₂ atmosphere. Then the reaction was placed at a distance (app. 5 cm) from 23W CFL lamp and the mixture was stirred for 24 h at room temperature. Then the reaction

was added 5 mL H₂O, extracted with DCM (3 × 10 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **3r**, **3t**.

3.5 General Procedure for the hydroboration of **1ab**, **1ac**, **1aj-1al**, **1am**, **1an**.


To a 10 mL Schlenk flask equipped with alkenes (0.2 mmol, 1.0 equiv.), NHC-borane (44 mg, 0.4 mmol, 2 equiv.), PhSSPh (8.8 mg, 0.04 mmol, 0.2 equiv.) and THF (2 mL) under N₂ atmosphere. Then the reaction was placed at a distance (app. 5 cm) from 10W blue LEDs (410-420 nm) lamp and the mixture was stirred for 24 h at room temperature. Then the reaction was added 5 mL H₂O, extracted with DCM (3 × 10 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **3ab**, **3ac**, **3aj-3al**, **3am**, **3an**.

3.6 General Procedure for the hydroboration of **1ad-1ai**.

To a 10 mL Schlenk flask equipped with alkenes (0.2 mmol, 1.0 equiv.), NHC-borane (28.6 mg, 0.26 mmol, 1.3 equiv.), PhSSPh (4.4 mg, 0.02 mmol, 0.1 equiv.) and in THF (2 mL) under N₂ atmosphere. Then the reaction was placed at a distance (app. 5 cm) from 10W blue LEDs (410-420 nm) lamp and the mixture was stirred for 24 h at room temperature. Then the reaction was added 5 mL H₂O, extracted with DCM (3 × 10 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **3ad-3ai**.


4. Gram scale and mechanistic experiments.

4.1 Gram scale experiment procedure.



To a 100 mL Schlenk flask equipped with **1a** (10 mmol, 1.0 equiv.), NHC-borane (1.43 g, 13 mmol, 1.3 equiv.), PhSSPh (220 mg, 1 mmol, 0.1 equiv.) in EtOH (50 mL) under N₂ atmosphere. Then the reaction was placed at a distance (app. 5 cm) from 23W CFL lamp and the mixture was stirred for 24 h at room temperature. Then the reaction was concentrated under reduced pressure. The residue was purified by column chromatography (Petroleum ether: EtOAc) on silica gel to obtain the products **3a** in 70% yield.

4.2 radical trapping experiment procedure.



To a 10 mL Schlenk flask equipped with **1a** (0.2 mmol, 1.0 equiv.), NHC-borane (28.6

mg, 0.26 mmol, 1.3 equiv.), PhSSPh (4.4 mg, 0.02 mmol, 0.1 equiv.) and TEMPO (47 mg, 0.6 mmol, 3.0 equiv.) in EtOH (2 mL) under N₂ atmosphere. Then the reaction was placed at a distance (app. 5 cm) from 23W CFL lamp and the mixture was stirred for 24 h at room temperature. No desired product was obtained by TLC detected and we found the boryl radical, thiyl radical, and intermediate A radical-trapping products.






Figure S1. HRMS data of the reaction mixture

5. Characterization data of products.




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(1-methoxy-1-oxo-3-phenylpropan-2-yl)dihydroborate (**3a**): Colorless liquid (50 mg, 92% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ¹H NMR (600 MHz, CDCl₃) δ 7.19 (d, *J* = 4.5 Hz, 4H), 7.10 – 7.06 (m, 1H), 6.79 (s, 2H), 3.71 (s, 6H), 3.36 (s, 3H), 3.11 (dd, *J* = 14.3, 10.2 Hz, 1H), 2.70 (dd, *J* = 14.3, 4.2 Hz, 1H), 2.19 (s, 1H), 1.88 – 1.39 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 181.94, 144.74, 128.46, 127.91, 125.06, 120.46, 50.37, 39.11, 35.97. ¹¹B NMR (193 MHz, CDCl₃) δ -25.00 (t, *J* = 89.7 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -25.0. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.19 (d, *J* = 4.4 Hz, 4H), 7.10 – 7.06 (m, 1H), 6.79 (s, 2H), 3.71 (s, 6H), 3.36 (s, 3H), 3.11 (dd, *J* = 14.3, 10.2 Hz, 1H), 2.70 (dd, *J* = 14.3, 4.3 Hz, 1H), 2.21–2.17 (m, 1H), 1.76 – 1.52 (m, 2H). Characterization agrees with previous reports for this compound.⁴




(3-(4-chlorophenyl)-1-methoxy-1-oxopropan-2-yl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (3b): Colorless liquid (50 mg, 82% yield); Gradient eluent: EtOAc/petroleum ether: 1/3 to 1/2; ^1H NMR (600 MHz, CDCl_3) δ 7.13 (q, $J = 8.5$ Hz, 4H), 6.81 (s, 2H), 3.72 (s, 6H), 3.34 (s, 3H), 3.04 (dd, $J = 14.3, 10.3$ Hz, 1H), 2.67 (dd, $J = 14.4, 4.2$ Hz, 1H), 2.13 (s, 1H), 1.87 – 1.39 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 181.6, 143.25, 130.61, 129.88, 127.92, 120.46, 50.39, 38.45, 35.99. ^{11}B NMR (193 MHz, CDCl_3) δ -25.09 (t, $J = 90.7$ Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -25.0. $^1\text{H}\{\text{H}\}$ NMR (600 MHz, CDCl_3) δ 7.13 (q, $J = 8.5$ Hz, 4H), 6.81 (s, 2H), 3.71 (s, 6H), 3.34 (s, 3H), 3.04 (dd, $J = 14.3, 10.3$ Hz, 1H), 2.67 (dd, $J = 14.4, 4.3$ Hz, 1H), 2.15 – 2.11 (m, 1H), 1.74 – 1.51 (m, 2H).

HRMS (ESI-TOF) m/z: [M + Na] $^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{BClN}_2\text{NaO}_2$ 329.1199; found: 329.1195.




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(3-(4-fluorophenyl)-1-methoxy-1-oxopropan-2-yl)dihydroborate (3c): Colorless liquid (43 mg, 74% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ^1H NMR (600 MHz, CDCl_3) δ 7.13 (dd, $J = 8.4, 5.7$ Hz, 2H), 6.86 (t, $J = 8.8$ Hz, 2H), 6.81 (s, 2H), 3.72 (s, 6H), 3.35 (s, 3H), 3.05 (dd, $J = 14.3, 10.3$ Hz, 1H), 2.67 (dd, $J = 14.3, 4.1$ Hz, 1H), 2.13 (s, 1H), 1.94 – 1.44 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 181.76, 161.67, 160.06, 140.36, 129.74 (d, $J = 7.6$ Hz), 120.45, 114.47 (d, $J = 21.1$ Hz), 50.36, 38.28, 35.98. ^{11}B NMR (193 MHz, CDCl_3) δ -25.11 (t, $J = 90.7$ Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -25.11. $^1\text{H}\{\text{H}\}$ NMR (600 MHz, CDCl_3) δ 7.13 (dd, $J = 8.4, 5.7$ Hz, 2H), 6.86 (t, $J = 8.8$ Hz, 2H), 6.81 (s, 2H), 3.72 (s, 6H), 3.35 (s, 3H), 3.05 (dd, $J = 14.3, 10.2$ Hz, 1H), 2.67 (dd, $J = 14.4, 4.3$ Hz, 1H), 2.13 (td, $J = 10.6, 5.0$ Hz, 1H), 1.60 (d, $J = 19.2$ Hz, 2H). ^{19}F NMR (565 MHz, CDCl_3) δ -119.13.

HRMS (ESI-TOF) m/z: [M + Na] $^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{BFN}_2\text{NaO}_2$ 313.1494; found: 313.1496.




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(1-ethoxy-1-oxo-3-phenylpropan-2-yl)dihydroborate (**3d**): Colorless liquid (41.2 mg, 72% yield); Gradient eluent: EtOAc/petroleum ether: 1/3 to 1/2; ¹H NMR (600 MHz, CDCl₃) δ 7.22 – 7.17 (m, 4H), 7.08 (t, *J* = 6.6 Hz, 1H), 6.80 (s, 2H), 3.80 (dd, *J* = 15.1, 7.3 Hz, 2H), 3.73 (s, 6H), 3.11 (dd, *J* = 14.3, 10.3 Hz, 1H), 2.71 (dd, *J* = 14.3, 4.0 Hz, 1H), 2.19 (s, 1H), 1.86 – 1.40 (m, 2H), 0.97 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 181.59, 144.87, 128.54, 127.83, 124.98, 120.36, 58.52, 39.15, 36.02, 14.33. ¹¹B NMR (193 MHz, CDCl₃) δ -25.00 (t, *J* = 89.7 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -25.00. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.21 – 7.17 (m, 4H), 7.08 (t, *J* = 6.7 Hz, 1H), 6.80 (s, 2H), 3.80 (ddd, *J* = 26.2, 10.8, 7.1 Hz, 2H), 3.73 (s, 6H), 3.11 (dd, *J* = 14.3, 10.3 Hz, 1H), 2.71 (dd, *J* = 14.3, 4.2 Hz, 1H), 2.19 (dt, *J* = 10.3, 5.1 Hz, 1H), 1.62 (d, *J* = 13.9 Hz, 2H), 0.97 (t, *J* = 7.1 Hz, 3H).

Characterization agrees with previous reports for this compound.⁴




(1-(cinnamyloxy)-1-oxo-3-phenylpropan-2-yl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (**3e**): Colorless liquid (53 mg, 71% yield); Gradient eluent: EtOAc/petroleum ether: 1/3 to 1/2; ¹H NMR (600 MHz, CDCl₃) δ 7.32 – 7.29 (m, 4H), 7.23 (dd, *J* = 6.8, 3.0 Hz, 3H), 7.19 (t, *J* = 7.6 Hz, 2H), 7.09 (t, *J* = 7.2 Hz, 1H), 6.71 (s, 2H), 6.42 (d, *J* = 15.9 Hz, 1H), 6.01 (dt, *J* = 15.9, 6.2 Hz, 1H), 4.48 (ddd, *J* = 13.2, 6.4, 1.3 Hz, 1H), 4.41 (ddd, *J* = 13.2, 6.1, 1.4 Hz, 1H), 3.71 (s, 6H), 3.15 (dd, *J* = 14.3, 10.2 Hz, 1H), 2.76 (dd, *J* = 14.3, 4.1 Hz, 1H), 2.27 (s, 1H), 1.46 (dd, *J* = 97.8, 48.3 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 181.27, 144.76, 136.63, 132.55, 128.58, 128.56, 127.91, 127.76, 126.44, 125.07, 124.74, 120.35, 63.31, 39.19, 36.07. ¹¹B NMR (193 MHz, CDCl₃) δ -24.96 (t, *J* = 91.1 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -24.95. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.32 – 7.29 (m, 4H), 7.24 (dd, *J* = 10.8, 5.2 Hz, 3H), 7.19 (t, *J* = 7.6 Hz, 2H), 7.09 (t, *J* = 7.2 Hz, 1H), 6.71 (s, 2H), 6.43 (d, *J* = 15.9 Hz, 1H), 6.01 (dt, *J* = 15.9, 6.2 Hz, 1H), 4.48 (ddd, *J* = 13.2, 6.4, 1.1 Hz, 1H), 4.41 (dd, *J* = 13.2, 6.0 Hz, 1H), 3.71 (s, 6H), 3.15 (dd, *J* = 14.3, 10.2 Hz, 1H), 2.76 (dd, *J* = 14.3, 4.2 Hz, 1H), 2.26 (td, *J* = 10.4, 5.1 Hz, 1H), 1.64 (s, 2H).

Characterization agrees with previous reports for this compound.⁴




(1-carboxy-2-phenylethyl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (**3f**): White solid (41.5 mg, 81% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 2/1; ¹H NMR (600 MHz, CDCl₃) δ 7.22 (q, *J* = 4.2 Hz, 2H), 7.22 (s, 2H), 7.11 (ddd, *J* = 8.5, 6.3, 2.2 Hz, 1H), 6.68 (s, 2H), 3.62 (s, 6H), 3.05 (dd, *J* = 14.5, 10.5 Hz, 1H), 2.73 (dd, *J* = 14.6, 4.0 Hz, 1H), 2.17 (s, 1H), 1.92 – 1.42 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 188.67, 144.74, 128.59, 127.87, 125.08, 120.51, 38.64, 35.84. ¹¹B NMR (193 MHz, CDCl₃) δ -24.58 (t, *J* = 89.7 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -24.58. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.22 (q, *J* = 4.2 Hz, 2H), 7.22 (s, 2H), 7.11 (dt, *J* = 8.4, 2.0 Hz, 1H), 6.68 (s, 2H), 3.62 (s, 6H), 3.05 (dd, *J* = 14.5, 10.4 Hz, 1H), 2.73 (dd, *J* = 14.6, 4.0 Hz, 1H), 2.17 (td, *J* = 10.2, 4.8 Hz, 1H), 1.65 (d, *J* = 39.8 Hz, 2H).

Characterization agrees with previous reports for this compound.⁹



(1-carboxy-2-(p-tolyl)ethyl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (**3g**): White solid (30 mg, 55% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 2/1; ¹H NMR (600 MHz, CDCl₃) δ 7.12 (d, *J* = 7.9 Hz, 2H), 7.03 (d, *J* = 7.8 Hz, 2H), 6.69 (s, 2H), 3.64 (s, 6H), 3.01 (dd, *J* = 14.5, 10.5 Hz, 1H), 2.68 (dd, *J* = 14.6, 3.8 Hz, 1H), 2.29 (s, 3H), 2.16 (s, 1H), 1.92 – 1.41 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 188.57, 141.65, 134.28, 128.55, 128.44, 120.47, 38.20, 35.87, 21.01. ¹¹B NMR (193 MHz, CDCl₃) δ -24.60 (t, *J* = 89.7 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -24.61. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.12 (d, *J* = 7.9 Hz, 2H), 7.02 (d, *J* = 7.9 Hz, 2H), 6.69 (s, 2H), 3.64 (s, 6H), 3.02 (dd, *J* = 14.5, 10.5 Hz, 1H), 2.68 (dd, *J* = 14.6, 3.9 Hz, 1H), 2.29 (s, 3H), 2.15 (td, *J* = 10.3, 4.8 Hz, 1H), 1.64 (d, *J* = 38.3 Hz, 2H).


HRMS (ESI-TOF) m/z: [M + Na]⁺ caclcd. for C₁₅H₂₁BN₂NaO₂ 295.1588; found: 295.1587.



(1-carboxy-2-(4-chlorophenyl)ethyl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)


dihydroborate (**3h**): White solid (40 mg, 53% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 2/1; ¹H NMR (600 MHz, CDCl₃) δ 7.16 (q, *J* = 8.6 Hz, 4H), 6.75 (s, 2H), 3.65 (s, 6H), 2.99 (dd, *J* = 14.5, 10.5 Hz, 1H), 2.69 (dd, *J* = 14.5, 4.1 Hz, 1H), 2.11 (s, 1H), 1.96 – 1.60 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 187.72, 143.15, 130.62, 130.04, 127.84, 120.52, 38.05, 35.87. ¹¹B NMR (193 MHz, CDCl₃) δ -24.71 (t, *J* = 93.6 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -24.74. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.16 (q, *J* = 8.6 Hz, 4H), 6.75 (s, 2H), 3.65 (s, 6H), 2.99 (dd, *J* = 14.5, 10.5 Hz, 1H), 2.69 (dd, *J* = 14.5, 4.2 Hz, 1H), 2.11 (dd, *J* = 12.4, 7.9 Hz, 1H), 1.63 (d, *J* = 36.5 Hz, 2H).

HRMS (ESI-TOF) m/z: [M + Na]⁺ caclcd. for C₁₅H₂₁BN₂NaO₂ 315.1042; found: 315.1030.



(1-amino-1-oxo-3-phenylpropan-2-yl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)
dihydroborate (**3i**): Colorless liquid (36.3 mg, 71% yield); Gradient eluent:
DCM/MeOH: 30/1 to 10/1; ¹H NMR (600 MHz, CDCl₃) δ 7.18 (d, *J* = 4.5 Hz, 4H),
7.07 (dt, *J* = 8.6, 4.4 Hz, 1H), 6.73 (s, 2H), 5.27 (s, 2H), 3.69 (s, 6H), 2.94 (dd, *J* = 14.4,
10.1 Hz, 1H), 2.71 (dd, *J* = 14.4, 4.7 Hz, 1H), 2.07 (s, 1H), 1.84 – 1.41 (m, 2H). ¹³C
NMR (151 MHz, CDCl₃) δ 185.16, 144.24, 128.38, 127.95, 125.16, 120.56, 39.67,
36.13. ¹¹B NMR (193 MHz, CDCl₃) δ -24.59 (t, *J* = 88.8 Hz). ¹¹B{¹H} NMR (193 MHz,
CDCl₃) δ -24.59. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.18 (d, *J* = 4.6 Hz, 4H), 7.07
(dt, *J* = 8.6, 4.5 Hz, 1H), 6.73 (s, 2H), 5.26 (s, 2H), 3.69 (s, 6H), 2.95 (dd, *J* = 14.4, 10.0
Hz, 1H), 2.71 (dd, *J* = 14.4, 4.8 Hz, 1H), 2.07 (dq, *J* = 10.2, 5.2 Hz, 1H), 1.63 (d, *J* =
4.6 Hz, 2H).


Characterization agrees with previous reports for this compound.⁴




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(3-oxo-1-phenylbutan-2-yl)dihydroborate (**3j**):
Colorless liquid (30.2 mg, 59% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to
1/1; ¹H NMR (600 MHz, CDCl₃) δ 7.17 (t, *J* = 7.5 Hz, 2H), 7.12 (d, *J* = 7.0 Hz, 2H),
7.07 (t, *J* = 7.2 Hz, 1H), 6.79 (s, 2H), 3.71 (s, 6H), 3.09 (dd, *J* = 14.6, 9.6 Hz, 1H), 2.65
(dd, *J* = 14.6, 4.6 Hz, 1H), 2.58 (s, 1H), 2.01 (s, 3H), 1.85 – 1.51 (m, 2H). ¹³C NMR
(151 MHz, CDCl₃) δ 217.42, 144.40, 128.27, 127.95, 125.05, 120.62, 38.35, 36.16,
28.29. ¹¹B NMR (193 MHz, CDCl₃) δ -25.35 (t, *J* = 89.7 Hz). ¹¹B{¹H} NMR (193 MHz,

CDCl_3) δ -25.35. $^1\text{H}\{\text{B}^{11}\}$ NMR (600 MHz, CDCl_3) δ 7.17 (t, $J = 7.5$ Hz, 2H), 7.11 (d, $J = 7.2$ Hz, 2H), 7.06 (t, $J = 7.2$ Hz, 1H), 6.79 (s, 2H), 3.71 (s, 6H), 3.09 (dd, $J = 14.6, 9.6$ Hz, 1H), 2.65 (dd, $J = 14.6, 4.7$ Hz, 1H), 2.57 (td, $J = 10.1, 5.0$ Hz, 1H), 2.00 (s, 3H), 1.61 (d, $J = 33.7$ Hz, 2H).

Characterization agrees with previous reports for this compound.⁴




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(1-(4-methoxyphenyl)-3-oxobutan-2-yl)dihydroborate (**3k**): Colorless liquid (24 mg, 42% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ^1H NMR (600 MHz, CDCl_3) δ 7.03 (d, $J = 8.6$ Hz, 2H), 6.79 (s, 2H), 6.72 (d, $J = 8.6$ Hz, 2H), 3.73 (s, 3H), 3.70 (s, 6H), 3.01 (dd, $J = 14.4, 9.7$ Hz, 1H), 2.57 (dd, $J = 14.4, 4.5$ Hz, 1H), 2.53 (s, 1H), 1.98 (s, 3H), 1.86 – 1.38 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 217.51, 157.18, 136.62, 129.10, 120.64, 113.38, 55.22, 37.43, 36.15, 28.33. ^{11}B NMR (193 MHz, CDCl_3) δ -25.36 (t, $J = 89.7$ Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -25.36. $^1\text{H}\{\text{B}^{11}\}$ NMR (600 MHz, CDCl_3) δ 7.02 (d, $J = 8.6$ Hz, 2H), 6.79 (s, 2H), 6.72 (d, $J = 8.6$ Hz, 2H), 3.73 (s, 3H), 3.70 (s, 6H), 3.01 (dd, $J = 14.5, 9.6$ Hz, 1H), 2.57 (dd, $J = 14.5, 4.7$ Hz, 1H), 2.52 (td, $J = 9.9, 5.0$ Hz, 1H), 1.98 (s, 3H), 1.59 (d, $J = 28.3$ Hz, 2H). HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for $\text{C}_{16}\text{H}_{23}\text{BN}_2\text{NaO}_2$ 309.1745; found: 309.1745.




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(2-oxochroman-3-yl)dihydroborate (**3l**): White solid (39 mg, 76% yield); Gradient eluent: EtOAc/petroleum ether: 1/1 to 2/1; ^1H NMR (600 MHz, CDCl_3) δ 7.12 (dd, $J = 13.2, 7.5$ Hz, 2H), 6.99 (t, $J = 7.8$ Hz, 1H), 6.88 (d, $J = 8.0$ Hz, 1H), 6.77 (s, 2H), 3.65 (s, 6H), 3.24 (d, $J = 12.3$ Hz, 1H), 2.71 (d, $J = 15.2$ Hz, 1H), 2.37 (s, 1H), 1.77 – 1.28 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 178.24, 152.38, 128.45, 126.83, 124.07, 123.32, 120.69, 115.43, 35.97, 30.63. ^{11}B NMR (193 MHz, CDCl_3) δ -26.07 (t, $J = 91.3$ Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -26.07. $^1\text{H}\{\text{B}^{11}\}$ NMR (600 MHz, CDCl_3) δ 7.12 (dd, $J = 13.1, 7.5$ Hz, 2H), 6.99 (t, $J = 7.8$ Hz, 1H), 6.88 (d, $J = 7.9$ Hz, 1H), 6.76 (s, 2H), 3.65 (s, 6H), 3.24 (dd, $J = 15.2, 6.2$ Hz, 1H), 2.71 (d, $J = 15.2$ Hz, 1H), 2.37 (dd, $J = 12.8, 5.9$ Hz, 1H), 1.47 (d, $J = 32.7$ Hz, 2H).

Characterization agrees with previous reports for this compound.⁴




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)dihydroborate (**3m**): White solid (49.1 mg, 92% yield); Gradient eluent: EtOAc/petroleum ether: 1/1 to 2/1; ¹H NMR (600 MHz, CDCl₃) δ 7.14 (t, *J* = 7.9 Hz, 1H), 7.10 (d, *J* = 7.2 Hz, 1H), 6.91 (t, *J* = 7.3 Hz, 1H), 6.82 (d, *J* = 8.0 Hz, 1H), 6.73 (s, 2H), 3.60 (s, 6H), 3.23 (s, 3H), 3.20 (d, *J* = 14.7 Hz, 1H), 2.61 (d, *J* = 14.8 Hz, 1H), 2.24 (s, 1H), 1.60–1.10 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 180.17, 141.17, 127.97, 127.94, 126.11, 121.69, 120.30, 112.96, 35.80, 32.48, 29.10. ¹¹B NMR (193 MHz, CDCl₃) δ -27.81 (t, *J* = 90.7 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -26.81. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.14 (t, *J* = 7.9 Hz, 1H), 7.10 (d, *J* = 7.2 Hz, 1H), 6.91 (t, *J* = 7.3 Hz, 1H), 6.82 (d, *J* = 8.0 Hz, 1H), 6.73 (s, 2H), 3.59 (s, 6H), 3.23 (s, 3H), 3.20 (q, *J* = 14.7 Hz, 1H), 2.61 (d, *J* = 14.8 Hz, 1H), 2.24 (dd, *J* = 11.7, 5.6 Hz, 1H), 1.35 (d, *J* = 39.3 Hz, 2H).

Characterization agrees with previous reports for this compound.⁹




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(7-((3-methylbut-2-en-1-yl)oxy)-2-oxochroman-3-yl)dihydroborate (**3n**): White solid (47.9 mg, 70% yield); Gradient eluent: EtOAc/petroleum ether: 1/1 to 2/1; ¹H NMR (600 MHz, CDCl₃) δ 7.01 (d, *J* = 8.2 Hz, 1H), 6.77 (s, 2H), 6.58 (dd, *J* = 8.2, 2.5 Hz, 1H), 6.49 (d, *J* = 2.5 Hz, 1H), 5.47 (t, *J* = 7.3 Hz, 1H), 4.46 (d, *J* = 6.7 Hz, 2H), 3.67 (s, 6H), 3.16 (dd, *J* = 14.5, 5.0 Hz, 1H), 2.64 (d, *J* = 14.9 Hz, 1H), 2.34 (s, 1H), 1.78 (s, 3H), 1.72 (s, 3H), 1.66 – 1.25 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 178.26, 157.93, 152.95, 138.11, 128.69, 120.65, 119.70, 116.00, 109.60, 102.36, 64.94, 36.01, 29.88, 25.85, 18.22. ¹¹B NMR (193 MHz, CDCl₃) δ -26.00 (t, *J* = 91.7 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -25.99. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.01 (d, *J* = 8.2 Hz, 1H), 6.77 (s, 2H), 6.58 (dd, *J* = 8.2, 2.5 Hz, 1H), 6.49 (d, *J* = 2.5 Hz, 1H), 5.47 (t, *J* = 6.7 Hz, 1H), 4.46 (d, *J* = 6.7 Hz, 2H), 3.67 (s, 6H), 3.16 (dd, *J* = 14.9, 6.1 Hz, 1H), 2.64 (d, *J* = 14.9 Hz, 1H), 2.35 (dd, *J* = 12.4, 6.0 Hz, 1H), 1.78 (s, 3H), 1.72 (s, 3H), 1.48 (d, *J* = 26.1 Hz, 2H).

HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd. for C₁₉H₂₅BN₂NaO₃ 363.1850; found: 363.1837.




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(7-methoxy-8-(3-methylbut-2-en-1-yl)-2-oxochroman-3-yl)dihydroborate (**3o**): White solid (65.3 mg, 92% yield); Gradient eluent: EtOAc/petroleum ether: 1/1 to 2/1; ¹H NMR (600 MHz, CDCl₃) δ 6.92 (d, *J* = 8.2 Hz, 1H), 6.76 (s, 2H), 6.55 (d, *J* = 8.3 Hz, 1H), 5.18 (t, *J* = 7.0 Hz, 1H), 3.79 (s, 3H), 3.65 (s, 6H), 3.40 (dd, *J* = 14.0, 7.5 Hz, 1H), 3.32 (dd, *J* = 14.0, 6.6 Hz, 1H), 3.17 (dd, *J* = 14.2, 4.8 Hz, 1H), 2.65 (d, *J* = 14.8 Hz, 1H), 2.31 (s, 1H), 1.77 (s, 3H), 1.63 (s, 3H), 1.56 – 1.29 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 178.35, 156.31, 150.56, 131.02, 125.44, 122.92, 120.60, 116.95, 116.52, 105.43, 55.79, 35.93, 30.48, 25.82, 22.26, 17.91. ¹¹B NMR (193 MHz, CDCl₃) δ -26.12 (t, *J* = 91.7 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -26.11. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 6.92 (d, *J* = 8.2 Hz, 1H), 6.76 (s, 2H), 6.54 (d, *J* = 8.2 Hz, 1H), 5.18 (t, *J* = 7.0 Hz, 1H), 3.79 (s, 3H), 3.65 (s, 6H), 3.40 (dd, *J* = 14.0, 7.4 Hz, 1H), 3.32 (dd, *J* = 14.0, 6.6 Hz, 1H), 3.17 (dd, *J* = 14.7, 6.0 Hz, 1H), 2.65 (d, *J* = 14.6 Hz, 1H), 2.32 (dd, *J* = 12.1, 5.8 Hz, 1H), 1.77 (s, 3H), 1.63 (s, 3H), 1.44 (d, *J* = 35.9 Hz, 2H).

HRMS (ESI-TOF) m/z: [M + Na]⁺ caclcd. for C₂₀H₂₉BN₂NaO₃ 377.2007; found: 377.2008.




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(7-oxo-6,7-dihydro-5H-furo[3,2-g]chromen-6-yl)dihydroborate (**3p**): White solid (52.1 mg, 88% yield); Gradient eluent: EtOAc/petroleum ether: 1/1 to 2/1; ¹H NMR (600 MHz, CDCl₃) δ 7.54 (d, *J* = 2.2 Hz, 1H), 7.34 (s, 1H), 7.09 (s, 1H), 6.78 (s, 2H), 6.68 (dd, *J* = 2.1, 0.8 Hz, 1H), 3.68 (s, 6H), 3.34 (d, *J* = 10.8 Hz, 1H), 2.84 (d, *J* = 14.8 Hz, 1H), 2.39 (s, 1H), 1.60 – 1.13 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 178.39, 153.75, 150.37, 144.74, 123.11, 120.63, 120.04, 119.61, 106.27, 98.70, 36.01, 30.87. ¹¹B NMR (193 MHz, CDCl₃) δ -26.25 (t, *J* = 90.7 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -26.26. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.54 (d, *J* = 2.1 Hz, 1H), 7.34 (s, 1H), 7.09 (s, 1H), 6.78 (s, 2H), 6.68 (d, *J* = 1.2 Hz, 1H), 3.68 (s, 6H), 3.34 (dd, *J* = 14.7, 5.8 Hz, 1H), 2.84 (d, *J* = 14.8 Hz, 1H), 2.39 (dd, *J* = 12.9, 5.5 Hz, 1H), 1.47 (d, *J* = 59.1 Hz, 2H).

HRMS (ESI-TOF) m/z: [M + Na]⁺ caclcd. for C₁₆H₁BN₂NaO₃ 319.1224; found: 319.1221.




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(4-oxo-4-(phenylamino)butan-2-yl)dihydroborate (**3q**): White solid (36 mg, 38% yield); Gradient eluent: EtOAc/petroleum ether: 2/1 to 1/1; ¹H NMR (600 MHz, CDCl₃) δ 7.83 (s, 1H), 7.53 (d, *J* = 7.9 Hz, 2H), 7.28 (d, *J* = 7.7 Hz, 2H), 7.03 (t, *J* = 7.4 Hz, 1H), 6.79 (s, 2H), 3.76 (s, 6H), 2.32 (dd, *J*

δ = 13.8, 7.3 Hz, 1H), 2.24 (dd, J = 13.6, 6.8 Hz, 1H), 1.76 – 1.35 (m, 2H), 1.19 (s, 1H), 0.84 (d, J = 6.6 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 174.65, 138.77, 128.82, 123.38, 120.32, 119.60, 48.69, 36.14, 22.57. ^{11}B NMR (193 MHz, CDCl_3) δ -24.03 (t, J = 84.0 Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -24.03. $^1\text{H}\{\text{H}\}$ NMR (600 MHz, CDCl_3) δ 7.82 (s, 1H), 7.53 (d, J = 7.9 Hz, 2H), 7.29 – 7.26 (m, 2H), 7.03 (t, J = 7.3 Hz, 1H), 6.79 (s, 2H), 3.76 (s, 6H), 2.32 (dd, J = 13.9, 7.4 Hz, 1H), 2.24 (dd, J = 13.9, 6.9 Hz, 1H), 1.58 – 1.40 (m, 2H), 1.18 (td, J = 13.1, 6.6 Hz, 1H), 0.84 (d, J = 6.9 Hz, 3H). HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for $\text{C}_{15}\text{H}_{22}\text{BN}_3\text{NaO}$ 294.1754; found: 294.1750.




(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)(4-((3-fluorophenyl)amino)-4-oxobutan-2-yl)dihydroborate (**3r**): White solid (38 mg, 66% yield); Gradient eluent: EtOAc/petroleum ether: 1/3 to 1/2; ^1H NMR (600 MHz, CDCl_3) δ 8.07 (s, 1H), 7.54 (d, J = 11.3 Hz, 1H), 7.19 (td, J = 8.1, 6.5 Hz, 1H), 7.14 (dd, J = 7.7, 1.0 Hz, 1H), 6.79 (s, 2H), 6.73 – 6.69 (m, 1H), 3.74 (s, 6H), 2.32 (dd, J = 13.8, 7.5 Hz, 1H), 2.26 (dd, J = 13.8, 6.6 Hz, 1H), 1.56 (dd, J = 163.4, 74.7 Hz, 2H), 1.16 (d, J = 4.4 Hz, 1H), 0.81 (d, J = 6.8 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 174.86, 163.02 (d, J = 241.6 Hz) 140.39 (d, J = 12.1 Hz), 129.77 (d, J = 9.1 Hz), 120.37, 114.72, 109.90 (d, J = 241.6 Hz), 106.93 (d, J = 27.2 Hz), 48.66, 36.11, 22.51. ^{11}B NMR (193 MHz, CDCl_3) δ -24.04 (t, J = 84.2 Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -24.04. $^1\text{H}\{\text{H}\}$ NMR (600 MHz, CDCl_3) δ 8.05 (s, 1H), 7.53 (d, J = 11.2 Hz, 1H), 7.21 – 7.17 (m, 1H), 7.14 (d, J = 8.2 Hz, 1H), 6.79 (s, 2H), 6.71 (td, J = 8.6, 2.0 Hz, 1H), 3.74 (s, 6H), 2.31 (dd, J = 13.9, 7.5 Hz, 1H), 2.26 (dd, J = 13.9, 6.7 Hz, 1H), 1.59 – 1.40 (m, 2H), 1.20 – 1.14 (m, 1H), 0.82 (d, J = 7.0 Hz, 3H).

HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for $\text{C}_{15}\text{H}_{21}\text{BFN}_3\text{NaO}$ 312.1659; found: 312.1656.




(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)(4-((4-ethylphenyl)amino)-4-oxobutan-2-yl)dihydroborate (**3s**): White solid (20 mg, 33% yield); Gradient eluent: EtOAc/petroleum ether: 1/1 to 2/1; ^1H NMR (600 MHz, CDCl_3) δ 7.72 (s, 1H), 7.43 (d, J = 8.3 Hz, 2H), 7.11 (d, J = 8.3 Hz, 2H), 6.79 (s, 2H), 3.76 (s, 6H), 2.59 (q, J = 7.6 Hz, 2H), 2.31 (dd, J = 13.8, 7.3 Hz, 1H), 2.22 (dd, J = 13.6, 6.8 Hz, 1H), 1.83 – 1.46 (m, 2H), 1.20 (d, J = 7.6 Hz, 3H), 1.18 – 1.15 (m, 1H), 0.84 (d, J = 6.6 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 174.47, 139.41, 136.37, 128.13, 120.30, 119.78, 48.62, 36.15, 28.30, 22.56, 15.74.


¹¹B NMR (193 MHz, CDCl₃) δ -24.03 (t, *J* = 83.3 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -24.03. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.71 (s, 1H), 7.44 (d, *J* = 8.2 Hz, 2H), 7.11 (d, *J* = 8.3 Hz, 2H), 6.79 (s, 2H), 3.77 (s, 6H), 2.59 (q, *J* = 7.6 Hz, 2H), 2.31 (dd, *J* = 13.9, 7.3 Hz, 1H), 2.22 (dd, *J* = 13.9, 7.0 Hz, 1H), 1.59 – 1.41 (m, 2H), 1.21 (d, *J* = 7.6 Hz, 3H), 1.19 – 1.15 (m, 1H), 0.85 (d, *J* = 6.9 Hz, 3H). HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for C₁₇H₂₆BN₃NaO 322.2061; found: 322.2060.



(4-((4-bromo-3-methylphenyl)amino)-4-oxobutan-2-yl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (**3t**): White solid (31.8 mg, 44% yield); Gradient eluent: EtOAc/petroleum ether: 1/3 to 1/1; ¹H NMR (600 MHz, CDCl₃) δ 7.87 (s, 1H), 7.47 (d, *J* = 1.9 Hz, 1H), 7.39 (d, *J* = 8.6 Hz, 1H), 7.26 (dd, *J* = 8.3, 2.3 Hz, 1H), 6.80 (s, 2H), 3.75 (s, 6H), 2.34 (s, 3H), 2.32 – 2.28 (m, 1H), 2.24 (dd, *J* = 13.6, 6.5 Hz, 1H), 1.66 – 1.33 (m, 2H), 1.16 (d, *J* = 4.3 Hz, 1H), 0.81 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 174.68, 138.18, 138.03, 132.38, 121.77, 120.35, 118.59, 118.29, 48.69, 36.14, 23.02, 22.53. ¹¹B NMR (193 MHz, CDCl₃) δ -24.07 (t, *J* = 85.0 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -24.06. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.86 (s, 1H), 7.47 (s, 1H), 7.39 (d, *J* = 8.6 Hz, 1H), 7.25 (d, *J* = 7.0 Hz, 1H), 6.80 (s, 2H), 3.75 (s, 6H), 2.34 (s, 3H), 2.30 (dd, *J* = 13.9, 7.5 Hz, 1H), 2.24 (dd, *J* = 13.9, 6.7 Hz, 1H), 1.59 – 1.39 (m, 2H), 1.15 (dt, *J* = 13.4, 6.7 Hz, 1H), 0.82 (d, *J* = 6.9 Hz, 3H). HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for C₁₆H₂₃BBN₃NaO 386.1010; found: 386.1004.




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(2-(phenylsulfonyl)ethyl)dihydroborate (**3u**): Colorless liquid (32.7 mg, 59% yield); Gradient eluent: EtOAc/petroleum ether: 1/1 to 2/1; ¹H NMR (600 MHz, CDCl₃) δ 7.87 (dd, *J* = 8.3, 1.2 Hz, 2H), 7.59 – 7.57 (m, 1H), 7.51 (dd, *J* = 10.0, 3.6 Hz, 2H), 6.80 (s, 2H), 3.69 (s, 6H), 3.06 – 3.03 (m, 2H), 1.65 – 1.30 (m, 2H), 0.67 (s, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 139.90, 132.86, 128.84, 128.11, 123.18, 120.43, 60.23, 35.93. ¹¹B NMR (193 MHz, CDCl₃) δ -27.88 (t, *J* = 86.3 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -27.87. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.88 (d, *J* = 7.3 Hz, 2H), 7.57 (d, *J* = 7.4 Hz, 1H), 7.51 (t, *J* = 7.7 Hz, 2H), 6.80 (s, 2H), 3.70 (s, 6H), 3.07 – 3.02 (m, 2H), 1.33 (d, *J* = 20.1 Hz, 2H), 0.74 – 0.62 (m, 2H). HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd. for C₁₃H₁₉BN₂NaO₂S 301.1153; found: 301.1153.




(1-cyano-2-phenylethyl)(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)dihydroborate (**3v**): Colorless liquid (36.4 mg, 76% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ^1H NMR (600 MHz, CDCl_3) δ 7.28 (d, $J = 4.6$ Hz, 4H), 7.18 (dt, $J = 8.6, 3.7$ Hz, 1H), 6.85 (s, 2H), 3.83 (s, 6H), 2.87 (dd, $J = 14.0, 4.6$ Hz, 1H), 2.81 (dd, $J = 13.8, 10.5$ Hz, 1H), 1.88 (s, 1H), 1.83 – 1.34 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 142.51, 129.11, 128.55, 128.25, 125.97, 120.97, 40.03, 36.39. ^{11}B NMR (193 MHz, CDCl_3) δ -25.89 (t, $J = 90.7$ Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -25.89. $^1\text{H}\{\text{H}\}$ NMR (600 MHz, CDCl_3) δ 7.28 (d, $J = 4.5$ Hz, 4H), 7.18 (dd, $J = 7.6, 4.2$ Hz, 1H), 6.85 (s, 2H), 3.83 (s, 6H), 2.87 (dd, $J = 14.0, 4.8$ Hz, 1H), 2.82 (dd, $J = 13.9, 10.3$ Hz, 1H), 1.88 (qd, $J = 9.9, 4.8$ Hz, 1H), 1.69 (d, $J = 39.0$ Hz, 2H).

Characterization agrees with previous reports for this compound.⁴



(1-cyano-2-(p-tolyl)ethyl)(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)dihydroborate (**3w**): Colorless liquid (40.4 mg, 80% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ^1H NMR (600 MHz, CDCl_3) δ 7.18 (d, $J = 7.9$ Hz, 2H), 7.09 (d, $J = 7.8$ Hz, 2H), 6.86 (s, 2H), 3.84 (s, 6H), 2.83 (dd, $J = 14.0, 4.5$ Hz, 1H), 2.77 (dd, $J = 13.8, 10.5$ Hz, 1H), 2.31 (s, 3H), 1.86 (s, 1H), 1.79-1.49 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 139.47, 135.33, 129.19, 128.95, 128.40, 120.94, 39.62, 36.40, 21.07. ^{11}B NMR (193 MHz, CDCl_3) δ -25.91 (t, $J = 90.7$ Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -25.91. $^1\text{H}\{\text{H}\}$ NMR (600 MHz, CDCl_3) δ 7.18 (d, $J = 7.9$ Hz, 2H), 7.09 (d, $J = 7.8$ Hz, 2H), 6.86 (s, 2H), 3.84 (s, 6H), 2.83 (dd, $J = 14.0, 4.8$ Hz, 1H), 2.77 (dd, $J = 13.9, 10.5$ Hz, 1H), 2.31 (s, 3H), 1.86 (qd, $J = 10.0, 4.7$ Hz, 1H), 1.68 (d, $J = 41.9$ Hz, 2H).


Characterization agrees with previous reports for this compound.⁴



(1-cyano-2-(4-methoxyphenyl)ethyl)(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)dihydroborate (**3x**): Colorless liquid (47.7 mg, 89% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ^1H NMR (600 MHz, CDCl_3) δ 7.19 (d, $J = 8.6$ Hz, 2H), 6.85 (s, 2H), 6.82 (d, $J = 8.6$ Hz, 2H), 3.82 (s, 6H), 3.77 (s, 3H), 2.81 (dd, $J = 14.0, 4.6$ Hz, 1H), 2.74 (dd, $J = 14.0, 10.4$ Hz, 1H), 1.83 (s, 1H), 1.79 – 1.22 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 157.88, 134.74, 129.47, 129.22, 120.96, 113.66, 55.25, 39.16, 36.38. ^{11}B NMR (193 MHz, CDCl_3) δ -25.97 (t, $J = 90.7$ Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -25.97. $^1\text{H}\{\text{H}\}$ NMR (600 MHz, CDCl_3) δ 7.19 (d, $J = 8.5$ Hz,


2H), 6.85 (s, 2H), 6.82 (d, J = 8.5 Hz, 2H), 3.82 (s, 6H), 3.77 (s, 3H), 2.81 (dd, J = 14.1, 4.8 Hz, 1H), 2.74 (dd, J = 13.9, 10.5 Hz, 1H), 1.83 (td, J = 12.1, 4.7 Hz, 1H), 1.67 (d, J = 40.8 Hz, 2H).

Characterization agrees with previous reports for this compound.⁴




(2-(4-chlorophenyl)-1-cyanoethyl)(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)dihydroborate (3y): Colorless liquid (38.3 mg, 70% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ^1H NMR (600 MHz, CDCl_3) δ 7.22 (q, J = 8.5 Hz, 4H), 6.87 (s, 2H), 3.83 (s, 6H), 2.83 (dd, J = 14.0, 4.6 Hz, 1H), 2.77 (dd, J = 13.9, 10.3 Hz, 1H), 1.82 (s, 1H), 1.77 – 1.32 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 140.90, 131.63, 129.98, 128.79, 128.30, 120.99, 39.30, 36.39. ^{11}B NMR (193 MHz, CDCl_3) δ -26.00 (t, J = 91.7 Hz). $^{11}\text{B}\{^1\text{H}\}$ NMR (193 MHz, CDCl_3) δ -25.99. $^1\text{H}\{^{11}\text{B}\}$ NMR (600 MHz, CDCl_3) δ 7.22 (q, J = 8.5 Hz, 4H), 6.86 (s, 2H), 3.83 (s, 6H), 2.83 (dd, J = 14.1, 4.9 Hz, 1H), 2.77 (dd, J = 14.0, 10.3 Hz, 1H), 1.82 (ddd, J = 12.7, 9.8, 4.7 Hz, 1H), 1.66 (d, J = 39.4 Hz, 2H).

HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for $\text{C}_{14}\text{H}_{17}\text{BClN}_3\text{Na}$ 296.1096; found: 296.1099.




(1-cyano-2-(3-fluorophenyl)ethyl)(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)dihydroborate (3z): Colorless liquid (34.5 mg, 67% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ^1H NMR (600 MHz, CDCl_3) δ 7.23 (dd, J = 14.0, 7.9 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 6.97 (d, J = 10.0 Hz, 1H), 6.87 (s, 2H), 6.86 (dd, J = 8.4, 4.2 Hz, 1H), 3.83 (s, 6H), 2.86 (dd, J = 14.1, 4.7 Hz, 1H), 2.80 (dd, J = 14.0, 10.4 Hz, 1H), 1.86 (s, 1H), 1.78 – 1.39 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 162.81 (d, J = 244.6 Hz), 145.05 (d, J = 7.6 Hz), 129.62 (d, J = 7.6 Hz), 128.75, 124.28 (d, J = 3.0 Hz), 121.00, 115.32 (d, J = 21.1 Hz), 112.81 (d, J = 21.1 Hz), 39.70 (d, J = 1.5 Hz), 36.39. ^{11}B NMR (193 MHz, CDCl_3) δ -25.94 (t, J = 90.7 Hz). $^{11}\text{B}\{^1\text{H}\}$ NMR (193 MHz, CDCl_3) δ -25.94. $^1\text{H}\{^{11}\text{B}\}$ NMR (600 MHz, CDCl_3) δ 7.23 (dd, J = 14.0, 7.9 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 6.97 (d, J = 10.0 Hz, 1H), 6.87 (s, 2H), 6.86 (dd, J = 8.4, 4.2 Hz, 1H), 3.83 (s, 6H), 2.86 (dd, J = 14.1, 4.9 Hz, 1H), 2.80 (dd, J = 14.0, 10.3 Hz, 1H), 1.86 (ddd, J = 12.7, 9.9, 4.8 Hz, 1H), 1.67 (d, J = 40.8 Hz, 2H). ^{19}F NMR (565 MHz, CDCl_3) δ -114.06.

Characterization agrees with previous reports for this compound.⁴




(1-cyano-2-(naphthalen-2-yl)ethyl)(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl) dihydroborate (**3aa**): Colorless liquid (44.9 mg, 78% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ^1H NMR (600 MHz, CDCl_3) δ 7.77 (dd, $J = 12.6, 8.7$ Hz, 3H), 7.71 (s, 1H), 7.45 – 7.37 (m, 3H), 6.78 (s, 2H), 3.81 (s, 6H), 3.00 (qd, $J = 14.1, 7.6$ Hz, 2H), 1.97 (s, 1H), 1.92 – 1.50 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 140.06, 133.64, 132.17, 129.09, 127.77, 127.67, 127.60, 127.49, 126.64, 125.75, 125.09, 120.94, 40.19, 36.39. ^{11}B NMR (193 MHz, CDCl_3) δ -25.84 (t, $J = 90.7$ Hz). $^{11}\text{B}\{^1\text{H}\}$ NMR (193 MHz, CDCl_3) δ -25.85. $^1\text{H}\{^{11}\text{B}\}$ NMR (600 MHz, CDCl_3) δ 7.80 (d, $J = 8.9$ Hz, 2H), 7.46 (dd, $J = 8.4, 6.6$ Hz, 1H), 7.45 – 7.39 (m, 2H), 6.80 (s, 2H), 3.83 (s, 6H), 3.05 (dd, $J = 14.1, 5.0$ Hz, 1H), 3.00 (dd, $J = 14.0, 10.2$ Hz, 1H), 1.99 (qd, $J = 9.9, 4.8$ Hz, 1H), 1.72 (d, $J = 42$, 2H).

Characterization agrees with previous reports for this compound.¹⁰




(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)(2-phenyl-(phenylsulfonyl)vinyl) dihydroborate (**3ab**): Colorless liquid (34 mg, 48% yield); Gradient eluent: EtOAc/petroleum ether: 1/4 to 1/2; ^1H NMR (600 MHz, CDCl_3) δ 7.84 (d, $J = 7.3$ Hz, 2H), 7.52 (t, $J = 7.4$ Hz, 1H), 7.46 (t, $J = 7.5$ Hz, 2H), 7.11 (t, $J = 7.3$ Hz, 2H), 7.05 (t, $J = 7.3$ Hz, 1H), 6.90 (d, $J = 7.1$ Hz, 2H), 6.76 (s, 2H), 3.65 (s, 6H), 2.86 (d, $J = 10.0$ Hz, 1H), 2.77 – 2.69 (m, 2H), 1.66 (dd, $J = 181.0, 96.7$ Hz, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 141.25, 141.23, 132.05, 128.90, 128.59, 128.10, 127.85, 125.55, 120.49, 37.43, 35.98. ^{11}B NMR (193 MHz, CDCl_3) δ -29.56 (t, $J = 90.7$ Hz). $^{11}\text{B}\{^1\text{H}\}$ NMR (193 MHz, CDCl_3) δ -29.56. $^1\text{H}\{^{11}\text{B}\}$ NMR (600 MHz, CDCl_3) δ 7.84 (d, $J = 7.3$ Hz, 2H), 7.52 (t, $J = 7.4$ Hz, 1H), 7.46 (t, $J = 7.5$ Hz, 2H), 7.11 (t, $J = 7.3$ Hz, 2H), 7.05 (t, $J = 7.3$ Hz, 1H), 6.90 (d, $J = 7.2$ Hz, 2H), 6.76 (s, 2H), 3.65 (s, 6H), 2.90 – 2.83 (dd, $J = 9.0, 5.1$ Hz, 1H), 2.78 – 2.68 (m, 2H), 1.64 (d, $J = 178.7$ Hz, 2H).

Characterization agrees with previous reports for this compound.¹⁰




(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)(2-(4-fluorophenyl)-1-(phenylsulfonyl)vinyl) dihydroborate (**3ac**): Colorless liquid (34 mg, 48% yield); Gradient eluent:

dihydroborate (**3ac**): Colorless liquid (33.5 mg, 45% yield); Gradient eluent: EtOAc/petroleum ether: 1/2 to 1/1; ¹H NMR (600 MHz, CDCl₃) δ 7.81 (d, *J* = 7.1 Hz, 2H), 7.52 (t, *J* = 7.4 Hz, 1H), 7.46 (t, *J* = 7.6 Hz, 2H), 6.89 – 6.82 (m, 2H), 6.82 – 6.74 (m, 3H), 6.78 (s, 2H), 3.67 (s, 6H), 2.79 (d, *J* = 11.5 Hz, 1H), 2.75 – 2.69 (m, 1H), 2.65 (s, 1H), 1.99 – 1.93 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 161.06 (d, *J* = 243.1 Hz), 141.23, 136.89 (d, *J* = 3.0 Hz), 132.10, 130.26 (d, *J* = 7.6 Hz), 128.62, 128.01, 120.54, 114.59, 114.45, 36.70, 35.99. ¹¹B NMR (193 MHz, CDCl₃) δ -29.56 (t, *J* = 90.7 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -29.57. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.81 (d, *J* = 7.2 Hz, 2H), 7.52 (t, *J* = 7.4 Hz, 1H), 7.46 (t, *J* = 7.5 Hz, 2H), 6.85 (dd, *J* = 8.5, 5.6 Hz, 2H), 6.82 – 6.75 (m, 3H), 6.78 (s, 2H), 3.67 (s, 6H), 2.79 (dd, *J* = 13.1, 3.0 Hz, 1H), 2.72 (dd, *J* = 13.0, 9.4 Hz, 1H), 2.66 (dt, *J* = 12.3, 3.2 Hz, 1H), 1.64 (d, *J* = 187.7 Hz, 2H). ¹⁹F NMR (565 MHz, CDCl₃) δ -117.98. HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for C₁₉H₂₂BFN₂NaO₂S 395.1377; found: 395.1383.



(1-(diethoxyphosphoryl)-2-phenylethyl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl) dihydroborate (**3ad**): Colorless liquid (31.3 mg, 45% yield); Gradient eluent: Dichloromethane/ methanol: 40/1 to 20/1; ¹H NMR (600 MHz, CDCl₃) δ 7.20 – 7.16 (m, 4H), 7.08 (t, *J* = 6.6 Hz, 1H), 6.67 (s, 2H), 4.05 (p, *J* = 7.1 Hz, 2H), 3.92 – 3.85 (m, 2H), 3.58 (s, 6H), 3.15 (t, *J* = 13.7 Hz, 1H), 2.61 (dd, *J* = 22.3, 12.3 Hz, 1H), 1.88 – 1.43 (m, 2H), 1.34 – 1.30 (m, 1H), 1.25 (t, *J* = 7.1 Hz, 3H), 1.16 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 144.10 (d, *J* = 16.6 Hz), 128.96, 127.65, 125.04, 120.12, 61.04 (d, *J* = 7.6 Hz), 60.01 (d, *J* = 6.0 Hz), 36.68 (d, *J* = 4.5 Hz), 35.85, 16.62 (d, *J* = 6.0 Hz), 16.47 (d, *J* = 6.0 Hz). ¹¹B NMR (193 MHz, CDCl₃) δ -28.61 (t, *J* = 86.9 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -28.60. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.20 – 7.16 (m, 4H), 7.07 (t, *J* = 6.7 Hz, 1H), 6.67 (s, 2H), 4.05 (p, *J* = 7.1 Hz, 2H), 3.92 – 3.85 (m, 2H), 3.58 (s, 6H), 3.15 (td, *J* = 14.2, 4.1 Hz, 1H), 2.61 (td, *J* = 12.6, 9.7 Hz, 1H), 1.67 – 1.36 (m, 2H), 1.34 – 1.31 (m, 1H), 1.25 (t, *J* = 7.1 Hz, 3H), 1.16 (t, *J* = 7.0 Hz, 3H). ³¹P NMR (243 MHz, CDCl₃) δ 44.09.


Characterization agrees with previous reports for this compound.¹⁰



(1-(diethoxyphosphoryl)-2-(p-tolyl)ethyl)(1,3-dimethyl-1H-imidazol-3-ium-2-


yl)dihydroborate (**3ae**): Colorless liquid (40 mg, 55% yield); Gradient eluent: Dichloromethane/ methanol: 40/1 to 20/1; ¹H NMR (600 MHz, CDCl₃) δ 7.07 (d, *J* = 7.8 Hz, 2H), 6.97 (d, *J* = 7.7 Hz, 2H), 6.66 (s, 2H), 4.03 (p, *J* = 7.1 Hz, 2H), 3.92 – 3.83 (m, 2H), 3.09 (t, *J* = 13.0 Hz, 1H), 2.56 (dd, *J* = 22.4, 12.3 Hz, 1H), 2.25 (s, 3H), 1.86 – 1.36 (m, 2H), 1.32 – 1.27 (m, 1H), 1.23 (t, *J* = 7.1 Hz, 3H), 1.15 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 140.91 (d, *J* = 16.6 Hz), 134.26, 128.77, 128.31, 120.09, 60.99 (d, *J* = 7.6 Hz), 59.99 (d, *J* = 6.0 Hz), 36.14 (d, *J* = 4.5 Hz), 35.87, 20.98, 16.59 (d, *J* = 6.0 Hz), 16.46 (dd, *J* = 6.0 Hz). ¹¹B NMR (193 MHz, CDCl₃) δ -28.57 (t, *J* = 88.2 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -28.57. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.07 (d, *J* = 7.8 Hz, 2H), 6.98 (d, *J* = 7.7 Hz, 2H), 6.66 (s, 2H), 4.03 (p, *J* = 7.1 Hz, 2H), 3.91 – 3.84 (m, 2H), 3.58 (s, 6H), 3.10 (td, *J* = 14.4, 4.0 Hz, 1H), 2.56 (dd, *J* = 22.3, 12.5 Hz, 1H), 2.26 (s, 3H), 1.64 – 1.34 (m, 2H), 1.30 (dd, *J* = 17.6, 6.7 Hz, 1H), 1.23 (t, *J* = 7.0 Hz, 3H), 1.15 (t, *J* = 7.1 Hz, 3H). ³¹P NMR (243 MHz, CDCl₃) δ 44.29.

HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for C₁₈H₃₀BN₂NaO₃P 387.1979; found: 387.1967.




(1-(diethoxyphosphoryl)-2-(4-fluorophenyl)ethyl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (**3af**): Colorless liquid (46 mg, 63% yield); Gradient eluent: Dichloromethane/ methanol: 40/1 to 20/1; ¹H NMR (600 MHz, CDCl₃) δ 7.17 – 7.13 (m, 2H), 6.86 (t, *J* = 8.3 Hz, 2H), 6.69 (s, 2H), 4.04 – 3.99 (m, 2H), 3.89 – 3.82 (m, 2H), 3.59 (s, 6H), 3.08 (t, *J* = 13.0 Hz, 1H), 2.58 (dd, *J* = 22.4, 12.7 Hz, 1H), 1.84 – 1.36 (m, 2H), 1.22 (t, *J* = 7.1 Hz, 4H), 1.14 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 160.85 (d, *J* = 241.6 Hz), 139.74 (d, *J* = 15.1 Hz), 130.26 (d, *J* = 7.6 Hz), 120.17, 114.22 (d, *J* = 21.1 Hz), 61.02 (d, *J* = 7.6 Hz), 60.00 (d, *J* = 6.0 Hz), 35.90 (d, *J* = 4.5 Hz), 35.86, 16.58 (d, *J* = 6.0 Hz), 16.45 (d, *J* = 6.0 Hz). ¹¹B NMR (193 MHz, CDCl₃) δ -28.65 (t, *J* = 87.8 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -28.65. ¹H{¹¹B} (600 MHz, CDCl₃) δ 7.15 (dd, *J* = 8.3, 5.7 Hz, 2H), 6.86 (t, *J* = 8.7 Hz, 2H), 6.69 (s, 2H), 4.01 (p, *J* = 7.0 Hz, 2H), 3.89 – 3.82 (m, 2H), 3.59 (s, 6H), 3.08 (t, *J* = 13.7 Hz, 1H), 2.58 (dd, *J* = 22.3, 12.8 Hz, 1H), 1.83 – 1.32 (m, 2H), 1.22 (t, *J* = 7.1 Hz, 4H), 1.14 (t, *J* = 7.1 Hz, 3H). ¹⁹F NMR (565 MHz, CDCl₃) δ -119.00. ³¹P NMR (243 MHz, CDCl₃) δ 43.78.

HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for C₁₇H₂₇BFN₂NaO₃P 391.1729; found: 391.1732.




(2-(4-chlorophenyl)-1-(diethoxyphosphoryl)ethyl)(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)dihydroborate (3ag): Colorless liquid (46.4 mg, 60% yield); Gradient eluent: Dichloromethane/ methanol: 40/1 to 20/1; ^1H NMR (600 MHz, CDCl_3) δ 7.15 – 7.11 (m, 4H), 6.69 (s, 2H), 4.01 (p, J = 7.1 Hz, 2H), 3.88 – 3.81 (m, 2H), 3.59 (s, 6H), 3.07 (td, J = 14.4, 3.4 Hz, 1H), 2.57 (dd, J = 22.3, 12.9 Hz, 1H), 1.84 – 1.31 (m, 2H), 1.26 – 1.19 (m, 4H), 1.13 (t, J = 7.1 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 142.65 (d, J = 16.6 Hz), 130.61, 130.38, 127.64, 120.18, 61.01 (d, J = 6.0 Hz), 60.02 (d, J = 6.0 Hz), 36.11 (d, J = 4.5 Hz), 35.88, 16.58 (d, J = 6.0 Hz), 16.45 (d, J = 7.6 Hz). ^{11}B NMR (193 MHz, CDCl_3) δ -28.63 (t, J = 88.8 Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -28.62. $^1\text{H}\{\text{H}\}$ NMR (600 MHz, CDCl_3) δ 7.18 – 7.14 (m, 4H), 6.72 (s, 2H), 4.04 (p, J = 7.1 Hz, 2H), 3.91 – 3.85 (m, 2H), 3.62 (s, 6H), 3.10 (td, J = 14.4, 4.4 Hz, 1H), 2.60 (td, J = 13.0, 9.3 Hz, 1H), 1.44 (dd, J = 81.7, 62.9 Hz, 2H), 1.24 (t, J = 7.1 Hz, 4H), 1.16 (t, J = 7.1 Hz, 3H). ^{31}P NMR (243 MHz, CDCl_3) δ 43.63.

HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for $\text{C}_{17}\text{H}_{27}\text{BClN}_2\text{NaO}_3\text{P}$ 407.1433; found: 407.1429.




(1-(diethoxyphosphoryl)-2-(4-(methoxycarbonyl)phenyl)ethyl)(1,3-dimethyl-1*H*-imidazol-3-ium-2-yl)dihydroborate (3ah): Colorless liquid (36 mg, 44% yield); Gradient eluent: Dichloromethane/ methanol: 40/1 to 20/1; ^1H NMR (600 MHz, CDCl_3) δ 7.87 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 6.69 (s, 2H), 4.03 (p, J = 7.0 Hz, 2H), 3.89 – 3.84 (m, 5H), 3.59 (s, 6H), 3.16 (t, J = 13.9 Hz, 1H), 2.67 (dd, J = 22.3, 12.6 Hz, 1H), 1.32 – 1.28 (m, 1H), 1.23 (t, J = 7.0 Hz, 3H), 1.14 (t, J = 7.0 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 167.41, 150.04 (d, J = 16.6 Hz), 129.05, 127.02, 120.20, 61.08 (d, J = 6.0 Hz), 60.09 (d, J = 7.6 Hz), 51.88, 36.87 (d, J = 4.5 Hz), 35.89, 16.59 (d, J = 6.0 Hz), 16.46 (d, J = 6.0 Hz). ^{11}B NMR (193 MHz, CDCl_3) δ -28.62 (t, J = 88.8 Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -28.62. $^1\text{H}\{\text{H}\}$ NMR (600 MHz, CDCl_3) δ 7.87 (d, J = 8.1 Hz, 2H), 7.28 (d, J = 8.1 Hz, 2H), 6.69 (s, 2H), 4.03 (p, J = 7.1 Hz, 2H), 3.90 – 3.84 (m, 5H), 3.60 (s, 6H), 3.17 (td, J = 14.3, 4.1 Hz, 1H), 2.67 (td, J = 12.8, 9.7 Hz, 1H), 1.62 – 1.35 (m, 2H), 1.31 – 1.27 (m, 1H), 1.23 (d, J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). ^{31}P NMR (243 MHz, CDCl_3) δ 43.39.

Characterization agrees with previous reports for this compound.¹⁰




(1-(diethoxyphosphoryl)-2-(naphthalen-2-yl)ethyl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (3ai): Colorless liquid (26 mg, 33% yield); Gradient eluent: Dichloromethane/ methanol: 40/1 to 20/1; ¹H NMR (600 MHz, CDCl₃) δ 7.74 (dd, *J* = 15.8, 8.0 Hz, 2H), 7.68 (d, *J* = 8.4 Hz, 1H), 7.63 (s, 1H), 7.42 – 7.34 (m, 3H), 6.61 (s, 2H), 4.09 (p, *J* = 7.1 Hz, 2H), 3.96 – 3.89 (m, 2H), 3.56 (s, 6H), 3.32 (t, *J* = 14.2 Hz, 1H), 2.79 (dd, *J* = 23.0, 11.1 Hz, 1H), 1.43 (d, *J* = 23.3 Hz, 1H), 1.26 (t, *J* = 7.1 Hz, 3H), 1.18 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 141.69, 141.58, 133.48, 131.76, 128.03, 127.45, 127.01, 126.91, 125.48, 124.65, 120.08, 61.09 (d, *J* = 6.0 Hz), 60.07 (d, *J* = 6.0 Hz), 36.87 (d, *J* = 4.5 Hz), 35.87, 16.64 (d, *J* = 6.0 Hz), 16.50 (d, *J* = 6.0 Hz). ¹¹B NMR (193 MHz, CDCl₃) δ -28.57 (t, *J* = 88.8 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -28.59. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.74 (dd, *J* = 15.6, 8.0 Hz, 2H), 7.68 (d, *J* = 8.4 Hz, 1H), 7.63 (s, 1H), 7.41 – 7.35 (m, 3H), 6.61 (s, 2H), 4.09 (p, *J* = 7.1 Hz, 2H), 3.93 (qd, *J* = 7.2, 2.8 Hz, 2H), 3.56 (s, 6H), 3.33 (td, *J* = 14.3, 3.8 Hz, 1H), 2.82 – 2.75 (m, 1H), 1.46 – 1.42 (m, 1H), 1.26 (t, *J* = 7.1 Hz, 3H), 1.18 (t, *J* = 7.1 Hz, 3H). ³¹P NMR (243 MHz, CDCl₃) δ 43.92.

Characterization agrees with previous reports for this compound.¹⁰




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(1,1,1-trifluoro-3-phenylpropan-2-yl)dihydroborate (3aj): Colorless liquid (32 mg, 57% yield); Gradient eluent: EtOAc/petroleum ether: 1/4 to 1/2; ¹H NMR (600 MHz, CDCl₃) δ 7.22 (d, *J* = 4.4 Hz, 4H), 7.14 – 7.10 (m, 1H), 6.71 (s, 2H), 3.58 (s, 6H), 3.02 (d, *J* = 12.9 Hz, 1H), 2.62 (t, *J* = 11.1 Hz, 1H), 1.64 (s, 1H), 1.64 – 1.32 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 143.45, 133.79 (q, *J* = 279.3 Hz), 129.04, 127.79, 125.20, 120.26, 36.66 (q, *J* = 4.0 Hz), 35.67. ¹¹B NMR (193 MHz, CDCl₃) δ -28.70 (t, *J* = 87.6 Hz). ¹¹B{¹H} NMR (193 MHz, CDCl₃) δ -28.71. ¹H{¹¹B} NMR (600 MHz, CDCl₃) δ 7.22 (d, *J* = 4.3 Hz, 4H), 7.14 – 7.10 (m, 1H), 6.71 (s, 2H), 3.58 (s, 6H), 3.02 (dd, *J* = 13.4, 4.6 Hz, 1H), 2.62 (dd, *J* = 13.4, 8.7 Hz, 1H), 1.67 – 1.61 (m, 1H), 1.42 (d, *J* = 94.0 Hz, 2H). ¹⁹F NMR (565 MHz, CDCl₃) δ -64.82.

Characterization agrees with previous reports for this compound.¹⁰




(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(1,1,1-trifluoro-3-(p-tolyl)propan-2-yl)dihydroborate (3ak): Colorless liquid (45 mg, 76% yield); Gradient eluent: EtOAc/petroleum ether: 1/4 to 1/2; ^1H NMR (600 MHz, CDCl_3) δ 7.12 (d, $J = 7.9$ Hz, 2H), 7.04 (d, $J = 7.9$ Hz, 2H), 6.72 (s, 2H), 3.60 (s, 6H), 2.98 (d, $J = 12.8$ Hz, 1H), 2.60 (dd, $J = 12.9, 8.7$ Hz, 1H), 2.30 (s, 3H), 1.63 (s, 1H), 1.58 – 1.27 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 140.34, 132.93 (q, $J = 279.3$ Hz), 134.46, 128.87, 128.49, 120.24, 36.22 (q, $J = 4.0$ Hz), 35.70, 21.02. $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -28.63. $^1\text{H}\{\text{B}\}$ NMR (600 MHz, CDCl_3) δ 7.11 (d, $J = 7.4$ Hz, 2H), 7.04 (d, $J = 7.4$ Hz, 2H), 6.72 (s, 2H), 3.60 (s, 6H), 2.98 (dd, $J = 13.5, 4.5$ Hz, 1H), 2.59 (dd, $J = 13.4, 8.5$ Hz, 1H), 2.30 (s, 3H), 1.63 (dd, $J = 11.6, 4.2$ Hz, 1H), 1.42 (d, $J = 93.3$ Hz, 2H). ^{19}F NMR (565 MHz, CDCl_3) δ -64.71.
HRMS (ESI-TOF) m/z: [M + Na] $^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{BF}_3\text{N}_2\text{Na}$ 319.1564; found: 319.1560.



(3-(4-chlorophenyl)-1,1,1-trifluoropropan-2-yl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (3al): ^1H NMR (600 MHz, CDCl_3) δ 7.18 (q, $J = 8.4$ Hz, 4H), 6.74 (s, 2H), 3.59 (s, 6H), 2.96 (d, $J = 12.8$ Hz, 1H), 2.59 (dd, $J = 12.8, 8.8$ Hz, 1H), 1.56 (s, 1H), 1.47 – 1.26 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 141.97, 133.02 (q, $J = 277.84$ Hz), 130.79, 130.49, 127.81, 120.33, 36.05 (q, $J = 4.0$ Hz), 35.69. ^{11}B NMR (193 MHz, CDCl_3) δ -28.78 (t, $J = 87.6$ Hz). $^{11}\text{B}\{\text{H}\}$ NMR (193 MHz, CDCl_3) δ -28.79. $^1\text{H}\{\text{B}\}$ NMR (600 MHz, CDCl_3) δ 7.18 (q, $J = 8.5$ Hz, 4H), 6.74 (s, 2H), 3.60 (s, 6H), 2.96 (dd, $J = 13.4, 4.7$ Hz, 1H), 2.59 (dd, $J = 13.4, 8.6$ Hz, 1H), 1.57 (dtd, $J = 16.1, 8.2, 4.2$ Hz, 1H), 1.38 (d, $J = 107.7$ Hz, 2H). ^{19}F NMR (565 MHz, CDCl_3) δ -64.77.


Characterization agrees with previous reports for this compound.¹⁰



(1,3-dimethyl-1H-imidazol-3-ium-2-yl)(2-phenyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)dihydroborate (3am): Colorless liquid (39 mg, 57% yield); Gradient eluent: Dichloromethane; ^1H NMR (600 MHz, CDCl_3) δ 7.13 (dt, $J = 15.1, 7.5$

Hz, 4H), 7.00 (t, J = 7.1 Hz, 1H), 6.72 (s, 2H), 3.74 (s, 6H), 2.86 (dd, J = 14.1, 10.9 Hz, 1H), 2.38 (dd, J = 14.0, 5.4 Hz, 1H), 1.87 – 1.46 (m, 2H), 1.14 (s, 6H), 1.08 (s, 6H), 0.60 (s, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 147.58, 128.20, 127.55, 124.36, 120.07, 81.47, 39.13, 36.14, 24.94, 24.49. ^{11}B NMR (193 MHz, CDCl_3) δ 36.12, -26.65 (t, J = 86.7 Hz). $^{11}\text{B}\{^1\text{H}\}$ NMR (193 MHz, CDCl_3) δ -26.65. $^1\text{H}\{^{11}\text{B}\}$ NMR (600 MHz, CDCl_3) δ 7.13 (dt, J = 15.1, 7.5 Hz, 4H), 6.99 (t, J = 7.1 Hz, 1H), 6.71 (s, 2H), 3.73 (s, 6H), 2.85 (dd, J = 14.1, 10.7 Hz, 1H), 2.38 (dd, J = 14.1, 5.5 Hz, 1H), 1.52 (d, J = 14.1 Hz, 2H), 1.14 (s, 6H), 1.08 (s, 6H), 0.60 (td, J = 10.8, 5.3 Hz, 1H).


Characterization agrees with previous reports for this compound.¹⁰



(2-(4-chlorophenyl)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)(1,3-dimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (3an): Colorless liquid (50.4 mg, 67% yield); Gradient eluent: Dichloromethane; ^1H NMR (600 MHz, CDCl_3) δ 7.07 (s, 4H), 6.73 (s, 2H), 3.73 (s, 6H), 2.79 (dd, J = 13.7, 11.0 Hz, 1H), 2.34 (dd, J = 14.1, 5.3 Hz, 1H), 1.78 – 1.31 (m, 2H), 1.12 (s, 6H), 1.05 (s, 6H), 0.53 (s, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 146.18, 129.82, 129.60, 127.51, 120.13, 81.53, 38.57, 36.15, 24.96, 24.47. ^{11}B NMR (193 MHz, CDCl_3) δ 35.60, -26.68 (t, J = 86.7 Hz). $^{11}\text{B}\{^1\text{H}\}$ NMR (193 MHz, CDCl_3) δ -26.68. $^1\text{H}\{^{11}\text{B}\}$ NMR (600 MHz, CDCl_3) δ 7.06 (s, 4H), 6.72 (s, 2H), 3.71 (s, 6H), 2.78 (t, J = 12.6 Hz, 1H), 2.33 (dd, J = 13.6, 5.4 Hz, 1H), 1.48 (d, J = 20.0 Hz, 2H), 1.10 (s, 6H), 1.04 (s, 6H), 0.51 (s, 1H).


HRMS (ESI-TOF) m/z: [M + Na]⁺ calcd for $\text{C}_{19}\text{H}_{29}\text{BClN}_2\text{NaO}_3$ 397.2001; found: 397.2000.

6.Characterization data of starting materials




7-((3-methylbut-2-en-1-yl)oxy)-2H-chromen-2-one (1n): White solid (503 mg, 75% yield); Gradient eluent: EtOAc/petroleum ether: 1/3 to 1/2; ^1H NMR (600 MHz, CDCl_3) δ 7.62 (d, J = 9.5 Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 6.84 (dd, J = 8.6, 2.2 Hz, 1H), 6.81 (s, 1H), 6.23 (d, J = 9.4 Hz, 1H), 5.46 (t, J = 6.7 Hz, 1H), 4.57 (d, J = 6.7 Hz, 2H), 1.80 (s, 3H), 1.76 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 162.14, 161.30, 155.88, 143.47, 139.30, 128.71, 118.64, 113.22, 112.97, 112.44, 101.57, 65.44, 25.83, 18.30.

Characterization agrees with previous reports for this compound.²




(*E*)-N-phenylbut-2-enamide (**1q**): White solid (338 mg, 70% yield); Gradient eluent: EtOAc/petroleum ether: 1/5 to 1/4; ¹H NMR (600 MHz, CDCl₃) δ 8.12 (s, 1H), 7.59 (d, *J* = 7.3 Hz, 2H), 7.28 (t, *J* = 7.9 Hz, 2H), 7.08 (t, *J* = 7.3 Hz, 1H), 6.95 (dq, *J* = 13.8, 6.9 Hz, 1H), 6.02 (dd, *J* = 15.1, 1.6 Hz, 1H), 1.83 (dd, *J* = 6.9, 1.6 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 164.59, 141.34, 138.23, 128.92, 125.66, 124.23, 120.26, 17.82. Characterization agrees with previous reports for this compound.¹¹




(*E*)-N-(3-fluorophenyl)but-2-enamide (**1r**): White solid (430 mg, 80% yield); Gradient eluent: EtOAc/petroleum ether: 1/5 to 1/4; ¹H NMR (600 MHz, CDCl₃) δ 8.04 (s, 1H), 7.53 (d, *J* = 10.0 Hz, 1H), 7.22 (s, 2H), 6.97 (dd, *J* = 13.9, 6.6 Hz, 1H), 6.78 (s, 1H), 5.99 (d, *J* = 15.1 Hz, 1H), 1.86 (d, *J* = 4.4 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 164.57, 162.95 (d, *J* = 244.6 Hz), 142.22, 139.69 (d, *J* = 10.6 Hz), 130.00 (d, *J* = 9.1 Hz), 125.22, 115.43, 110.93 (d, *J* = 21.1 Hz), 107.61 (d, *J* = 28.7 Hz), 17.85. ¹⁹F NMR (565 MHz, CDCl₃) δ -111.53.

HRMS (ESI-TOF) m/z: [M + Na]⁺ caclcd. for C₁₀H₁₀FN₂NaO 202.0639; found: 202.0635.




(*E*)-N-(4-ethylphenyl)but-2-enamide (**1s**): White solid (454 mg, 80% yield); Gradient eluent: EtOAc/petroleum ether: 1/5 to 1/4; ¹H NMR (600 MHz, CDCl₃) δ 8.15 (s, 1H), 7.50 (d, *J* = 7.8 Hz, 2H), 7.10 (d, *J* = 8.2 Hz, 2H), 6.94 (dq, *J* = 13.8, 6.8 Hz, 1H), 6.02 (dd, *J* = 15.1, 1.6 Hz, 1H), 2.59 (q, *J* = 7.6 Hz, 2H), 1.83 (dd, *J* = 6.9, 1.6 Hz, 3H), 1.20 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 164.50, 140.92, 140.23, 135.89, 128.21, 125.78, 120.40, 28.33, 17.79, 15.66.

HRMS (ESI-TOF) m/z: [M + Na]⁺ caclcd. for C₁₂H₁₅NNaO 212.1046; found: 212.1043.




(*E*)-N-(4-bromo-3-methylphenyl)but-2-enamide (**1t**): White solid (607 mg, 80% yield); Gradient eluent: EtOAc/petroleum ether: 1/5 to 1/4; ¹H NMR (600 MHz, CDCl₃) δ 7.72 (s, 1H), 7.48 (s, 1H), 7.40 (d, *J* = 8.6 Hz, 1H), 7.25 (d, *J* = 8.0 Hz, 1H), 6.96 (dq, *J* = 13.8, 6.9 Hz, 1H), 5.95 (dd, *J* = 15.1, 1.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 164.29, 141.91, 138.49, 137.26, 132.56, 125.29, 122.32, 119.46, 119.10, 23.01, 17.88. HRMS (ESI-TOF) m/z: [M + Na]⁺ caclcd. for C₁₁H₁₂BrNNaO 275.9994; found: 275.9994.




(*E*)-3-(p-tolyl)acrylonitrile (**1w**): White solid (146 mg, 34% yield); Gradient eluent: EtOAc/petroleum ether: 1/20 to 1/15; ¹H NMR (600 MHz, CDCl₃) δ 7.37 (d, *J* = 17.4 Hz, 1H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.21 (d, *J* = 8.0 Hz, 2H), 5.82 (d, *J* = 16.6 Hz, 1H), 2.39 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 150.55, 141.86, 130.90, 129.85, 127.36, 118.45, 95.09, 21.53.

Characterization agrees with previous reports for this compound.¹²




(*E*)-3-(p-tolyl)acrylonitrile (**1x**): White solid (143 mg, 30% yield); Gradient eluent: EtOAc/petroleum ether: 1/20 to 1/15; ¹H NMR (600 MHz, CDCl₃) δ 7.40 – 7.36 (m, 2H), 7.31 (d, *J* = 16.6 Hz, 1H), 6.94 – 6.86 (m, 2H), 5.70 (d, *J* = 16.6 Hz, 1H), 3.83 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 162.08, 150.05, 129.13, 126.36, 118.77, 114.55, 93.34, 55.48.

Characterization agrees with previous reports for this compound.¹²




(*E*)-3-(4-chlorophenyl)acrylonitrile (**1y**): White solid (196 mg, 40% yield); Gradient eluent: EtOAc/petroleum ether: 1/20 to 1/15; ¹H NMR (600 MHz, CDCl₃) δ 7.39 (s, 4H), 7.35 (d, *J* = 16.6 Hz, 1H), 5.86 (d, *J* = 16.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 149.14, 137.32, 132.00, 129.47, 128.56, 117.84, 97.03.

Characterization agrees with previous reports for this compound.¹²




(*E*)-3-(3-fluorophenyl)acrylonitrile (**1z**): White solid (198 mg, 45% yield); Gradient eluent: EtOAc/petroleum ether: 1/20 to 1/15; ¹H NMR (600 MHz, CDCl₃) δ 7.39 (q, *J* = 7.2 Hz, 1H), 7.37 (d, *J* = 16.8 Hz, 1H), 7.23 (d, *J* = 7.7 Hz, 1H), 7.14 (t, *J* = 8.7 Hz, 2H), 5.89 (d, *J* = 16.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 149.20 (d, *J* = 3.0 Hz), 135.62 (d, *J* = 7.6 Hz), 130.81 (d, *J* = 9.1 Hz), 123.43 (d, *J* = 3.0 Hz), 118.17 (d, *J* = 21.1 Hz), 117.61, 113.82, 113.67, 97.99.

Characterization agrees with previous reports for this compound.¹²




(E)-3-(naphthalen-2-yl)acrylonitrile (**1aa**): White solid (525 mg, 69% yield); Gradient eluent: EtOAc/petroleum ether: 1/20 to 1/15; ¹H NMR (600 MHz, CDCl₃) δ 7.86 – 7.81 (m, 4H), 7.56 – 7.51 (m, 4H), 5.96 (d, *J* = 16.6 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 150.61, 134.55, 133.10, 131.00, 129.71, 129.10, 128.74, 127.87, 127.13, 127.13, 122.22, 118.35, 96.32.

Characterization agrees with previous reports for this compound.¹²




(E)-(2-(phenylsulfonyl)vinyl)benzene (**1ab**): White solid (190 mg, 26% yield); Gradient eluent: EtOAc/petroleum ether: 1/20 to 1/10; ¹H NMR (600 MHz, CDCl₃) δ 7.95 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.69 (d, *J* = 15.4 Hz, 1H), 7.62 (t, *J* = 7.4 Hz, 1H), 7.55 (t, *J* = 7.7 Hz, 2H), 7.49 (dd, *J* = 7.8, 1.5 Hz, 2H), 7.43 – 7.37 (m, 3H), 6.86 (d, *J* = 15.4 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 142.53, 140.74, 133.41, 132.38, 131.25, 129.36, 129.12, 128.60, 127.68, 127.30.

Characterization agrees with previous reports for this compound.⁷




(E)-1-fluoro-4-(2-(phenylsulfonyl)vinyl)benzene (**1ac**): White solid (408 mg, 52% yield); Gradient eluent: EtOAc/petroleum ether: 1/20 to 1/10; ¹H NMR (600 MHz, CDCl₃) δ 7.95 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.65 (d, *J* = 15.3 Hz, 1H), 7.62 (d, *J* = 7.4 Hz, 1H), 7.56 (t, *J* = 7.7 Hz, 2H), 7.48 (dd, *J* = 8.7, 5.3 Hz, 2H), 7.09 (t, *J* = 8.6 Hz, 2H), 6.79 (d, *J* = 15.4 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 141.18, 140.66, 133.46, 130.63 (d, *J* = 9.1 Hz), 129.39, 128.66, 127.68, 127.07, 116.44, 116.29.

Characterization agrees with previous reports for this compound.⁷




diethyl (*E*)-styrylphosphonate (**1ad**): Yellow oil (144 mg, 60% yield); Gradient eluent: EtOAc/petroleum ether: 1/4 to 1/2; ¹H NMR (600 MHz, CDCl₃) δ 7.55 – 7.46 (m, 3H), 7.38 (dd, *J* = 5.0, 1.9 Hz, 3H), 6.25 (t, *J* = 17.6 Hz, 1H), 4.21 – 4.04 (m, 4H), 1.35 (t, *J* = 7.1 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 148.78 (d, *J* = 6.0 Hz), 134.95 (d, *J* = 22.7 Hz), 130.25, 128.87, 127.72, 114.97 (d, *J* = 191.8 Hz), 61.86 (d, *J* = 6.0 Hz), 16.42 (d, *J* = 6.0 Hz). ³¹P NMR (243 MHz, CDCl₃) δ 19.52.

Characterization agrees with previous reports for this compound.⁶




diethyl (*E*)-(4-methylstyryl)phosphonate (1ae**):** White solid (525 mg, 69% yield); Gradient eluent: EtOAc/petroleum ether: 1/4 to 1/2; ^1H NMR (600 MHz, CDCl_3) δ 7.44 (dd, $J = 22.5, 17.5$ Hz, 1H), 7.36 (d, $J = 7.9$ Hz, 2H), 7.15 (d, $J = 7.8$ Hz, 2H), 6.16 (t, $J = 17.7$ Hz, 1H), 4.19 – 4.01 (m, 4H), 2.33 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 148.80 (d, $J = 6.0$ Hz), 140.62, 132.13 (d, $J = 24.2$ Hz), 129.55, 127.69, 112.49 (d, $J = 193.3$ Hz), 61.79 (d, $J = 6.0$ Hz), 21.39, 16.38 (d, $J = 6.0$ Hz). ^{31}P NMR (243 MHz, CDCl_3) δ 20.01.

Characterization agrees with previous reports for this compound.⁶




diethyl (*E*)-(3-fluorostyryl)phosphonate (1af**):** Yellow oil (215 mg, 83% yield); Gradient eluent: EtOAc/petroleum ether: 1/4 to 1/2; ^1H NMR (600 MHz, CDCl_3) δ 7.45 (ddd, $J = 28.2, 13.9, 9.9$ Hz, 3H), 7.05 (t, $J = 8.6$ Hz, 2H), 6.15 (t, $J = 17.3$ Hz, 1H), 4.16 – 4.07 (m, 4H), 1.33 (t, $J = 7.1$ Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 163.85 (d, $J = 250.7$ Hz), 147.39 (d, $J = 6.0$ Hz), 131.12 (d, $J = 24.2$ Hz), 129.58 (d, $J = 7.6$ Hz), 115.97 (d, $J = 22.7$ Hz), 113.75 (d, $J = 194.8$ Hz), 61.87 (d, $J = 6.0$ Hz), 16.39 (d, $J = 7.6$ Hz). ^{31}P NMR (243 MHz, CDCl_3) δ 19.24. ^{19}F NMR (565 MHz, CDCl_3) δ -109.87 .

Characterization agrees with previous reports for this compound.⁶




diethyl (*E*)-(4-chlorostyryl)phosphonate (1ag**):** White solid (493 mg, 60% yield); Gradient eluent: EtOAc/petroleum ether: 1/4 to 1/2; ^1H NMR (600 MHz, CDCl_3) δ 7.43 (d, $J = 17.7$ Hz, 1H), 7.39 (d, $J = 7.6$ Hz, 2H), 7.32 (d, $J = 6.9$ Hz, 2H), 6.20 (t, $J = 16.9$ Hz, 1H), 4.15 – 4.04 (m, 4H), 1.32 (t, $J = 7.1$ Hz, 6H). ^{13}C NMR (151 MHz, CDCl_3) δ 147.20 (d, $J = 7.6$ Hz), 136.11, 133.34 (d, $J = 24.2$ Hz), 129.10, 128.88, 115.41 (d, $J = 191.8$ Hz), 61.92 (d, $J = 4.5$ Hz), 16.39 (d, $J = 6.0$ Hz). ^{31}P NMR (243 MHz, CDCl_3) δ 18.91.

Characterization agrees with previous reports for this compound.⁶




methyl (*E*)-4-(2-(diethoxyphosphoryl)vinyl)benzoate (1ah**):** White solid (626 mg, 70% yield); Gradient eluent: EtOAc/petroleum ether: 1/4 to 1/2; ¹H NMR (600 MHz, CDCl₃) δ 8.05 (d, *J* = 8.2 Hz, 2H), 7.56 (d, *J* = 7.9 Hz, 2H), 7.52 (q, *J* = 3.3 Hz, 1H), 6.37 (t, *J* = 17.3 Hz, 1H), 4.20 – 4.10 (m, 4H), 3.93 (s, 3H), 1.36 (t, *J* = 7.1 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 166.45, 147.21 (d, *J* = 6.0 Hz), 139.01 (d, *J* = 24.2 Hz), 131.39, 130.11, 127.59, 117.02 (d, *J* = 190.3 Hz), 62.03 (d, *J* = 6.0 Hz), 52.30, 16.43 (d, *J* = 6.0 Hz). ³¹P NMR (243 MHz, CDCl₃) δ 18.34.

Characterization agrees with previous reports for this compound.⁶




diethyl (*E*)-(2-(naphthalen-2-yl)vinyl)phosphonate (1ai**):** White solid (470 mg, 54% yield); Gradient eluent: EtOAc/petroleum ether: 1/4 to 1/2; ¹H NMR (600 MHz, CDCl₃) δ 7.89 (s, 1H), 7.85 – 7.80 (m, 3H), 7.70 – 7.62 (m, 2H), 7.52 – 7.47 (m, 2H), 6.36 (t, *J* = 17.5 Hz, 1H), 4.21 – 4.10 (m, 4H), 1.37 (t, *J* = 7.1 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 148.79 (d, *J* = 7.6 Hz), 134.21, 133.24, 132.31 (d, *J* = 24.2 Hz), 129.48, 128.68, 128.60, 127.78, 127.23, 126.74, 123.21, 114.05 (d, *J* = 191.8 Hz), 61.93 (d, *J* = 6.0 Hz), 16.45 (d, *J* = 7.6 Hz). ³¹P NMR (243 MHz, CDCl₃) δ 19.63.

Characterization agrees with previous reports for this compound.⁶



(*E*)-4,4,5,5-tetramethyl-2-styryl-1,3,2-dioxaborolane (1am**):** White solid (130 mg, 25% yield); Gradient eluent: EtOAc/petroleum ether: 1/50 to 1/25; ¹H NMR (600 MHz, CDCl₃) δ 7.50 (d, *J* = 7.3 Hz, 2H), 7.41 (d, *J* = 18.4 Hz, 1H), 7.34 (t, *J* = 7.4 Hz, 2H), 7.29 (t, *J* = 7.3 Hz, 1H), 6.18 (d, *J* = 18.4 Hz, 1H), 1.32 (s, 12H). ¹³C NMR (151 MHz, CDCl₃) δ 149.54, 137.50, 128.92, 128.59, 127.08, 83.37, 24.84. ¹¹B NMR (193 MHz, CDCl₃) δ 30.05.

Characterization agrees with previous reports for this compound.⁸





(*E*)-2-(4-chlorostyryl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1an**):** White solid (182 mg, 23% yield); Gradient eluent: EtOAc/petroleum ether: 1/50 to 1/25; ¹H NMR (600 MHz, CDCl₃) δ 7.41 (d, *J* = 8.5 Hz, 2H), 7.33 (d, *J* = 18.4 Hz, 1H), 7.30 (d, *J* = 8.5 Hz, 2H), 6.13 (d, *J* = 18.4 Hz, 1H), 1.31 (s, 12H). ¹³C NMR (151 MHz, CDCl₃) δ 152.69,



148.04, 144.59, 128.81, 128.24, 83.48, 24.82. ^{11}B NMR (193 MHz, CDCl_3) δ 30.31. Characterization agrees with previous reports for this compound.⁸


6. References:



1. P.-J. Xia, D. Song, Z.-P. Ye, Y.-Z. Hu, J.-A. Xiao, H.-Y. Xiang, X.-Q. Chen and H. Yang, *Angew. Chem. Int. Ed.*, 2020, **59**, 6706-6710.
2. X. Chen, L. Li, C. Pei, J. Li, D. Zou, Y. Wu and Y. Wu, *J. Org. Chem.* 2020, **86**, 2772-2783.
3. C. Zhu, J. Dong, X. Liu, L. Gao, Y. Zhao, J. Xie, S. Li and C. Zhu, *Angew. Chem. Int. Ed.*, 2020, **59**, 12817-12821.
4. G. Li, G. Huang, R. Sun and D. P. Curran, W. Dai, *Org. Lett.*, 2021, **23**, 4353-4357.
5. J. Yin, Y. Li, R. Zhang, K. Jin, C. Duan, *Synlett.*, 2014, **46**, 607-612.
6. W. A.-Maksoud, J. Mesnager, F. Jaber, C. Pinel, L. Djakovitch, *J. Organomet. Chem.*, 2009, **694**, 3222-3231.
7. N. Taniguchi, *Tetrahedron.*, 2014, **70**, 1984-1990.
8. S.-Y. Lin, J.-C. Liu, Y.-Y. Shi, T.-H. Hu, W. Yang, C.-Y. Wu, Y.-Y. Xie, F.-C. Hu and Y. Wang, CN, 11353372A.
9. S.-C. Ren, F.-L. Zhang, A.-Q. Xu, Y. Yang, M. Zheng, X. Zhou, Y. Fu and Y.-F. Wang, *Nat. Commun.*, 2019, **10**, 1934.
10. Y.-S. Huang, J. Wang, W.-X. Zeng, F.-L. Zhang, Y.-J. Yu, M. Zhang, X. Zhou and Y.-F. Wang, *Chem. Commun.*, 2019, **55**, 11904-11907.
11. F. Wang, H. Yang, H. Fu and Z. Pei, *Chem. Commun.*, 2013, **49**, 517-519.
12. J. B. Metternich, D. G. Artiukhin, M. C. Holland, M. V. Bremen-Kühne, J. Neugebauer and R. Gilmour, *J. Org. Chem.*, 2017, **82**, 9955-9977.



7. NMR Spectra



































































































































































































































































































































































































































¹H NMR (600 MHz, CDCl₃)



164.57
 163.76
 139.73
 139.66
 130.03
 129.97
 125.22
 115.43
 111.00
 110.86
 107.70
 107.51


–17.85



















¹³C NMR (151 MHz, CDCl₃)













^{13}C NMR (151 MHz, CDCl_3)






^1H NMR (600 MHz, CDCl_3)

























^{31}P NMR (243 MHz, CDCl_3)



—109.87






^{19}F NMR (565 MHz, CDCl_3)



















-3031

